<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Oncol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Oncology</journal-title>
</journal-title-group>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31803621</article-id>
<article-id pub-id-type="pmc">6876670</article-id>
<article-id pub-id-type="doi">10.3389/fonc.2019.01248</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Yves</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/139386/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schussler</surname>
<given-names>Olivier</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/645853/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hébert</surname>
<given-names>Jean-Louis</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/70810/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vallée</surname>
<given-names>Alexandre</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/350899/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Centre de Recherche Clinique, Grand Hôpital de l'Est Francilien</institution>, <addr-line>Meaux</addr-line>, <country>France</country></aff>
<aff id="aff2"><sup>2</sup><institution>Research Laboratory, Department of Cardiovascular Surgery, Geneva University Hospitals</institution>, <addr-line>Geneva</addr-line>, <country>Switzerland</country></aff>
<aff id="aff3"><sup>3</sup><institution>Institut de Cardiologie, Hôpital de la Pitié-Salpétrière</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff4"><sup>4</sup><institution>Hypertension and Cardiovascular Prevention Unit, Diagnosis and Therapeutic Center, Hôtel-Dieu Hospital, AP-HP</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff5"><sup>5</sup><institution>DACTIM-MIS, LMA, UMR CNRS 7348, CHU de Poitiers, Université de Poitiers</institution>, <addr-line>Poitiers</addr-line>, <country>France</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Daniel C. Hoessli, University of Karachi, Pakistan</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Michael P. Lisanti, University of Salford, United Kingdom; Shigeki Shimba, Nihon University, Japan; Elizabeth A. Schroder, University of Kentucky, United States; Youhua Liu, University of Pittsburgh, United States</p>
</fn>
<corresp id="c001">*Correspondence: Yves Lecarpentier <email>yves.c.lecarpentier@gmail.com</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>9</volume>
<elocation-id>1248</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>8</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Lecarpentier, Schussler, Hébert and Vallée.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Lecarpentier, Schussler, Hébert and Vallée</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Canonical WNT/β-catenin signaling is involved in most of the mechanisms that lead to the formation and development of cancer cells. It plays a central role in three cyclic processes, which are the cell division cycle, the immune cycle, and circadian rhythms. When the canonical WNT pathway is upregulated as in cancers, the increase in β-catenin in the nucleus leads to activation of the expression of numerous genes, in particular CYCLIN D1 and cMYC, where the former influences the G1 phase of the cell division cycle, and the latter, the S phase. Every stage of the immune cycle is disrupted by the canonical WNT signaling. In numerous cancers, the dysfunction of the canonical WNT pathway is accompanied by alterations of the circadian genes (CLOCK, BMAL1, PER). Induction of these cyclic phenomena leads to the genesis of thermodynamic mechanisms that operate far from equilibrium, and that have been called “dissipative structures.” Moreover, upregulation of the canonical WNT/β-catenin signaling is important in the myofibroblasts of the cancer stroma. Their differentiation is controlled by the canonical WNT /TGF-β1 signaling. Myofibroblasts present ultraslow contractile properties due to the presence of the non-muscle myosin IIA. Myofibroblats also play a role in the inflammatory processes, often found in cancers and fibrosis processes. Finally, upregulated canonical WNT deviates mitochondrial oxidative phosphorylation toward the Warburg glycolysis metabolism, which is characteristic of cancers. Among all these cancer-generating mechanisms, the upregulated canonical WNT pathway would appear to offer the best hope as a therapeutic target, particularly in the field of immunotherapy.</p>
</abstract>
<kwd-group>
<kwd>canonical WNT/β-catenin signaling</kwd>
<kwd>immune cycle</kwd>
<kwd>cell division cycle</kwd>
<kwd>myofibroblast</kwd>
<kwd>circadian rhythms</kwd>
<kwd>Warburg glycolysis</kwd>
<kwd>TGF-β1</kwd>
<kwd>immunotherapy</kwd>
</kwd-group>
<counts>
<fig-count count="6"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="234"></ref-count>
<page-count count="17"></page-count>
<word-count count="13658"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Since the discovery in 1982 of Int1 (WNT1a) as an oncogene reported in murine breast cancers, the canonical WNT/β-catenin pathway has often been found to be associated with cancer (<xref ref-type="bibr" rid="B1">1</xref>). Indeed, the canonical WNT pathway represents a key element in the genesis and development of a large number of human cancers. This makes the pathway a prime target in the search for new treatments for cancers, with high mortality and morbidity. In this review, we summarize the main findings regarding the dysfunctions of the canonical WNT signaling encountered in many cancers (<xref ref-type="fig" rid="F1">Figure 1</xref>). It has been reported that three major cyclic processes namely the cell division cycle (<xref ref-type="bibr" rid="B2">2</xref>–<xref ref-type="bibr" rid="B4">4</xref>), the immune cycle (<xref ref-type="bibr" rid="B5">5</xref>), and circadian rhythms (CRs) (<xref ref-type="bibr" rid="B6">6</xref>) become highly disturbed due to upregulation of the canonical WNT signaling. In the division cell cycle, canonical WNT signaling was initially described as a trigger for the G1 phase advancement through CYCLIN D1 and c-MYC transcription (<xref ref-type="bibr" rid="B7">7</xref>–<xref ref-type="bibr" rid="B11">11</xref>). This signaling is also involved at every stage of the immune cycle (<xref ref-type="bibr" rid="B12">12</xref>) and has led to the development of new modalities of immunotherapy. In addition, the dysfunction of the canonical WNT signaling is involved in the generation and development of the cancer stroma (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). In particular, aerobic glycolysis in tumor cells, which is partly responsible for shunting the mitochondrial oxidative phosphorylations [Warburg effect (<xref ref-type="bibr" rid="B15">15</xref>)], is related to the upregulation of the canonical WNT pathway. Finally, cancers fit into the thermodynamic framework of dissipative structures, in a manner similar to CRs or by generating oscillating phenomena in which canonical WNT pathway plays a central role (<xref ref-type="bibr" rid="B16">16</xref>). Since β-catenin regulates the expression of a considerable number of genes, such as CYCLIN D1 and cMYC, it is not surprising that this signaling interferes in numerous cancer-generating processes. Other pathways such as TGF-β1, activate the canonical WNT signaling, and will therefore potentially play a role upstream.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Overview of checkpoints of the canonical WNT/β-catenin signaling. The canonical WNT signaling is involved in at least six key areas of cancer pathophysiology, i.e., cell division cycle, immune cycle, circadian rhythms, cancer stroma, Warburg glycolysis, inflammation, and fibrosis.</p>
</caption>
<graphic xlink:href="fonc-09-01248-g0001"></graphic>
</fig>
</sec>
<sec id="s2">
<title>General Remarks About the Canonical WNT/β-Catenin Signaling</title>
<p>The canonical WNT signaling is involved in numerous physiological processes such as embryonic development, metabolism, cell fate and epithelial-mesenchymal transition (EMT). Upregulation of the canonical WNT pathway increases the level of β-catenin in both the cytoplasm and nucleus. The dysfunction of this pathway is involved in numerous pathological processes, particularly in cancers and fibrosis (<xref ref-type="bibr" rid="B17">17</xref>–<xref ref-type="bibr" rid="B20">20</xref>). The T-cell /lymphoid enhancer (TCF/LEF) transcription factors represent the final effectors of the canonical WNT signaling (<xref ref-type="fig" rid="F2">Figure 2</xref>). The destruction complex is composed of AXIN, tumor suppressor adenomatous polyposis coli (APC), and glycogen synthase kinase-3 (GSK-3β). GSK-3β exerts a tight control on the canonical WNT pathway. When WNT ligands are absent (“off state”), the cytosolic β-catenin is continuously ubiquitinylated leading to degradation via sequential phosphorylations by GSK-3β and caseine kinase 1 (CK1). The destruction complex phosphorylates β-catenin. Then β-catenin is degraded within the proteasome. When WNT ligands are present (“on state”), the WNT receptor interacts with Frizzled (FZL) and LDL receptor-related protein 5/6 (LRP5/6). WNT receptor is linked with Disheveled (DSH). This favors the disruption of the destruction complex and hinders degradation of β-catenin in the proteasome. β-catenin translocates to the nucleus and interferes with the TCF- LEF co-transcription factors. This leads to the stimulation of several β-catenin target genes (CYCLIN D1, c-MYC, PDK, MTC-1, MMP7, fibronectin, COX-2, AXIN-2) (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>) (<xref ref-type="fig" rid="F2">Figure 2</xref>). Mutations in the β-catenin gene (CTNNB1), mutations or loss-of-function in APC, AXIN-1 and AXIN-2 genes, all induce a continuous stimulation of the β-catenin signaling and have been reported in a large number of human cancers.</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>The canonical WNT/β-catenin pathway: “on” and “off” states. The canonical WNT pathway can be in either “on-state” or “off-state.” In the “off state”, i.e., in the absence of WNT ligand or in the presence of the active form of the glycogen synthase kinase-3β (GSK-3β) (i.e., the unphosphorylated form GSK-3β), cytosolic β-catenin is phosphorylated by GSK-3β and undergoes the destruction process into the proteasome. In the “on-state,” a WNT ligand binds both FZD and LRP5/6 receptors. GSK-3β is then under the inactive form (i.e., the phosphorylated form pGSK-3β). This leads to activation of the phosphoprotein Disheveled (DSH). DSH recruits the destruction complex (pGSK-3β + AXIN +APC) to the plasma membrane, where AXIN directly binds the cytoplasmic tail of LRP5/6. APC is the adenomatous polyposis coli. Activation of DSH leads to the inhibition of both phosphorylation and degradation of β-catenin. β-catenin accumulates into the cytosol and then translocates to the nucleus to bind the LEF-TCF co-transcription factors. This induces the WNT-response gene transcription of numerous genes such as <italic>CYCLIN D1, cMYC, MCT1, PDK, fibronectin</italic>. DKK1 inhibits the canonical WNT signaling.</p>
</caption>
<graphic xlink:href="fonc-09-01248-g0002"></graphic>
</fig>
<p>There is an opposed link between the canonical WNT pathway and PPARγ (<xref ref-type="bibr" rid="B23">23</xref>) (<xref ref-type="fig" rid="F3">Figure 3</xref>). This has been established in several cancers, neuro-degenerative diseases, cardiovascular diseases, fibrosis, and numerous other pathological processes (<xref ref-type="bibr" rid="B24">24</xref>–<xref ref-type="bibr" rid="B32">32</xref>). Transforming growth factor1 (TGF-β1) acts as a driver of these two major pathways (<xref ref-type="bibr" rid="B33">33</xref>). TGF-β1 and canonical WNT signaling are closely related, whereby the former activates the later. TGF-β1 receptors are the transmembrane proteins Type I (TGFβRI) and Type II (TGFβRII) (<xref ref-type="fig" rid="F3">Figure 3</xref>). Moreover, TGF-β1 activates both SMAD and non-SMAD pathways such as PI3K-AKT, MAPK and RHO, and downregulates PPARγ expression through the SMAD pathway (<xref ref-type="bibr" rid="B34">34</xref>). TGF-β1 and consequently the canonical WNT pathway play a central role in both cancers and fibrosis. In alveolar epithelial cells (AEC), TGF-β1 induces EMT and leads to lung fibrosis. In idiopathic pulmonary fibrosis, myofibroblasts induce lung fibrosis (<xref ref-type="bibr" rid="B35">35</xref>–<xref ref-type="bibr" rid="B37">37</xref>). In fibrotic lungs, TGF-β1-induced EMT in type II AEC results in differentiation of fibroblasts into myofibroblasts (<xref ref-type="bibr" rid="B38">38</xref>–<xref ref-type="bibr" rid="B42">42</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>WNT/β-catenin, TGF-β1, PI3K-AKT, SMAD, and PPARγ pathways. “On state” canonical WNT: In the presence of WNT ligands, the WNT receptor binds LRP5/6 and FZD receptors and initiates LRP phosphorylation and DSH-mediated Frizzled internalization. Then, the pGSK-3β/AXIN/APC destruction complex is dissociated. Phosphorylation of β-catenin is inhibited and β-catenin increases in the cytosol and then translocates to the nucleus. β-catenin binds the TCF-LEF transcription factors and induces the WNT-response gene transcription (CYCLIN D1, cMYC, PDK, MCT-1, AXIN2, fibronectin). DKK1 is activated by PPARγ and inhibits WNT. TGF-β1 binds the TGF-βR2 receptor, which recruits the TGF-βR1 receptor. This leads to the formation of a heterotetramer that phosphorylates SMAD. The SMAD complex then translocates to the nucleus and regulates the transcription of Smad target genes (CTGF, COL1A). PI3K-AKT pathway is a non-SMAD signaling and inactivates GSK-3β. PTEN inhibits PI3K-AKT and PPARγ inhibits AKT. PPARγ inhibits the β-catenin/TCF-LEF-induced activation of WNT target genes. TGF-β1 enhances the canonical WNT pathway through the inhibition of DKK1, itself an inhibitor of the canonical WNT signaling.</p>
</caption>
<graphic xlink:href="fonc-09-01248-g0003"></graphic>
</fig>
</sec>
<sec id="s3">
<title>Canonical WNT/β-Catenin Signaling, Cell Division Cycle and Cancer</title>
<sec>
<title>The Cell Division Cycle</title>
<p>The canonical WNT signaling plays a central role in the cell division cycle, particularly because the two nuclear β-catenin targets CYCLIN D1 and cMYC intervene at two key checkpoints of the cell cycle. CYCLIN D1 and cMYC act on the G1 phase and cMYC on the S phase (<xref ref-type="fig" rid="F4">Figure 4</xref>). An oscillator rotates the cell cycle, which consists of replicating the DNA. This then leads to a division into two cells, each containing a set of chromosomes (mitosis). In cancer cells, the regulation of the cell division cycle is impaired. Nurse, Hunt, and Hartwell have identified two factors that play an important role in mitosis, namely cyclins and cyclin-dependent kinases (Cdk) that control the transitions between the M, G1, S, and G2 phases of the cell division cycle (<xref ref-type="bibr" rid="B4">4</xref>). The key process is a feedback mechanism in which cyclins play a driving role in the cell division cycle (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). Each phase is controlled by a given CYCLIN/Cdk complex. The transition to a later phase of the cycle can only be made if the previous phase has been correctly completed. The cell can remain in the quiescent phase (Go) from which it exits when the level of growth factors is high enough and then allows the onset of the G1 phase. CYCLIN D1 is a key regulator of the checkpoint allowing the G1-S transition, via phosphorylation of the retinoblastoma protein (pRB) complex, thus increasing the cyclin E level. The transcription factor EF2 promotes the cell division cycle and the tumor suppressor pRB slows it down. Cdk kinases are activated by dephosphorylation (cdc25 phosphatase) and inhibited by phosphorylation (Wee1 kinase). The activation of each phase of the cell cycle is sequential and leads to inactivation of the previous phases.</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Cell division cycle. Four CYCLIN/Cdk kinase complexes control transitions between the 4 phases of the cell cycle, namely, M, G1, S (DNA replication), and G2 (separating the S phase from the M phase of mitosis). Each phase is controlled by a given CYCLIN/Cdk complex. The transition to a later phase of the cycle can develop only if the previous phase has been totally completed. The cell remains in the quiescent phase (Go) from which it exits when the level of growth factors becomes sufficient and then enters the G1 phase. The G1 phase is controlled by the CYCLIN D1/Cdk4 complex. Phase S is controlled by the CYCLIN E/Cdk2 complex. The G2 phase is controlled by the CYCLIN A/Cdk2 complex. The M phase is controlled by the cyclin B/Cdk1 complex. The canonical WNT signaling increases the expression of <italic>CYCLIN D1</italic> and <italic>cMYC</italic>. CYCLIN D1 induces the G1 phase whereas cMYC induces the S phase.</p>
</caption>
<graphic xlink:href="fonc-09-01248-g0004"></graphic>
</fig>
</sec>
<sec>
<title>WNT Transcriptional and Non-transcriptional Effects During the G1 Phase</title>
<p>Several pathways that regulate the cell proliferation act through the G1 phase (<xref ref-type="bibr" rid="B43">43</xref>). CYCLIN D1 is inhibited by p21 and p27, allowing the entry of the cell into the quiescence phase Go. The canonical WNT signaling triggers the G1 phase advancement through CYCLIN D1 and c-MYC transcriptional processes (<xref ref-type="fig" rid="F2">Figures 2</xref>, <xref ref-type="fig" rid="F4">4</xref>) (<xref ref-type="bibr" rid="B7">7</xref>–<xref ref-type="bibr" rid="B11">11</xref>). The canonical WNT pathway operates through the G1 phase by inducing the transcription of CYCLIN D1 and cMYC which are involved in cell proliferation (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B44">44</xref>–<xref ref-type="bibr" rid="B46">46</xref>). CYCLIN D1 has been one of the first transcriptional target genes of β-catenin to be reported in the colorectal cancer. The transcription factor c-MYC has a dual role in G1 phase by promoting CYCLIN D1 (<xref ref-type="bibr" rid="B47">47</xref>) and repressing p21 and p27 (<xref ref-type="bibr" rid="B45">45</xref>). pGSK-3β phosphorylates CYCLIN D1, CYCLIN E1, and c-MYC which are direct regulators of G1 progression (<xref ref-type="bibr" rid="B48">48</xref>–<xref ref-type="bibr" rid="B50">50</xref>).The phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT) pathway (PI3K-AKT) allows the G1-S transition phase of the cell cycle through the phosphorylation of GSK-3β (<xref ref-type="fig" rid="F4">Figure 4</xref>). GSK-3β phosphorylation (i.e., pGSK-3β is the inactivated form) decreases the degradation of β-catenin within the proteasome. Thus, TCF/LEF transcription factors are activated, which in turn leads to transcription of the target gene CYCLIN D1 (<xref ref-type="bibr" rid="B51">51</xref>). The phosphatase and tensin homolog (PTEM) also decreases cancer cell proliferation due the arrest of the cell cycle in G1 phase (<xref ref-type="fig" rid="F2">Figures 2</xref>, <bold>6</bold>).</p>
</sec>
<sec>
<title>Canonical WNT/β-Catenin Pathway, CYCLIN D1, and Cancer</title>
<p>CYCLIN D1 is considered as key target of the canonical WNT pathway. In endothelial cells, inorganic polyphosphate induces CYCLIN D1 synthesis via activation of the mTOR/WNT/β-catenin pathway (<xref ref-type="bibr" rid="B52">52</xref>). CYCLIN D1 is critical for intestinal adenoma development (<xref ref-type="bibr" rid="B53">53</xref>). The expression of both CYCLIN D1 and β-catenin, and the inactive pGSK-3β are significantly increased in papillary thyroid carcinoma primary tumors. Expressions of β-catenin and CYCLN D1 are correlated suggesting that β-catenin is a factor driving high CYCLIN D1 levels (<xref ref-type="bibr" rid="B54">54</xref>).</p>
</sec>
<sec>
<title>WNT/β-Catenin Signaling, Thermodynamics, Oscillations, and Dissipative Structures</title>
<p>A complete oscillating model of cyclins and cyclin-dependent kinases has been proposed by Gérard and Goldbeter (<xref ref-type="bibr" rid="B55">55</xref>). In the presence of a sufficient level of growth factors, the CYCLIN/Cdk complexes are activated sequentially. This complex system is capable of self-organization over time (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B56">56</xref>). The canonical WNT pathway modulates the cell cycle and conversely the cell cycle influences it. During the cell cycle, the expression of β-catenin oscillates and the maximum activation of β-catenin occurs at the G2/M transition (<xref ref-type="fig" rid="F4">Figure 4</xref>) (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B58">58</xref>). Moreover, expression of the β-catenin target AXIN2 also peaks at the G2/M transition (<xref ref-type="bibr" rid="B59">59</xref>). This requires the LRP6 phosphorylation by CYCLIN Y which mediates phosphorylation of LRP6. The CYCLIN D1/Cdk4 complex peaks at G1. The CYCLIN E/Cdk2 complex peaks at S (<xref ref-type="fig" rid="F4">Figure 4</xref>). The CYCLIN A/Cdk2 complex peaks at the end of S. The peaks of CYCLINS D1, E, and A follow each other, leading to the peak of CYCLIN B. The CYCLIN B/Cdk1 complex peaks at M and triggers the cell division (<xref ref-type="fig" rid="F4">Figure 4</xref>). The sustained oscillations of the various CYCLIN/Cdk complexes reflect the spontaneous self-organization of the cell division cycle over time. Thermodynamically, the cell division cycle represents a dissipative structure which behaves far from equilibrium (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B61">61</xref>). When a CYCLIN/Cdk complex is graphically represented in an X-Y manner as a function of another complex or as a function of the transcription factor E2F that induces the CYCLIN synthesis, there is an evolution toward a “limit cycle” regardless of initial conditions (<xref ref-type="bibr" rid="B55">55</xref>). Below a critical value of growth factor amount corresponding to a bifurcation point, the cell remains in a stable stationary state (quiescent phase Go). Beyond this point, the stationary system becomes unstable and the network of CYCLIN/Cdk complexes begins to oscillate autonomously. Cell proliferation persists as long as the concentration levels of growth factors allow. When the balance between the transcription factor E2F and the suppressor pRB tilts toward a certain level, sustained oscillations appear and the cell division cycle operates. However, even in the absence of growth factor, and under particular conditions, the cell cycle can start beyond a critical point in G1 (“Pardee restriction point”) (<xref ref-type="bibr" rid="B62">62</xref>). It must be mentioned that the canonical WNT pathway is involved in another important physiological process. Due to a periodic signal emitted by the segmentation clock, the WNT, NOTCH, and FGF oscillator synchronizes the activation of segmentation genes in successive steps. This leads to the formation of somites during the vertebrate segmentation (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>). This represents a supplementary oscillatory dissipative structure controlled by the WNT pathway.</p>
</sec>
</sec>
<sec id="s4">
<title>Canonical WNT/β-Catenin Signaling, Immune Cycle and Cancer</title>
<p>The immune cycle (<xref ref-type="fig" rid="F5">Figure 5</xref>) is defined by natural homeostatic oscillations of the immune system when chronic inflammation is occurring such as in cancers, and typically repeated every 7 days. This is due to the synchronous division of T cells over time. T-effector cells boost the immune activity. This is followed by T-regulatory cells that suppress the immune response (<xref ref-type="bibr" rid="B65">65</xref>). The cancer-immune cycle has been described by Chen and Mellman (<xref ref-type="bibr" rid="B5">5</xref>). The effects of the canonical WNT signaling on the immune cycle have been recently reported in an extensive review by Wang et al. (<xref ref-type="bibr" rid="B12">12</xref>). The canonical WNT signaling impacts all the steps of the immune cycle (<xref ref-type="fig" rid="F4">Figure 4</xref>), and we summarize here some of the numerous works concerning this subject. The canonical WNT pathway is a well-recognized cancer promoter as it regulates the cancer immune cycle at most of the checkpoints, composed of dendritic cells, T cells (especially effector T cells, T helper cells, and regulatory T cells) and tumor cells. The treatment of cancers by immunotherapy is being revolutionized by activating or reactivating the tumor-immune cycle (<xref ref-type="bibr" rid="B5">5</xref>).</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>The cancer immune cycle. Adapted and simplified schema of the tumor immune cycle proposed by Chen and Mellman (<xref ref-type="bibr" rid="B5">5</xref>) and by Wang et al. (<xref ref-type="bibr" rid="B12">12</xref>). Numerous studies have shown that the canonical WNT signaling is involved at each step of the tumor immune cycle: step 1 (tumor antigene release), step 2 (antigene presentation), step 3 (priming and activation), and steps 4 and 5 (trafficking, infiltration, and tumor cell elimination).</p>
</caption>
<graphic xlink:href="fonc-09-01248-g0005"></graphic>
</fig>
<p>Trafficking of T cells and their infiltration into tumor tissues lead to the antigen release and elimination of cancer cells (<xref ref-type="bibr" rid="B66">66</xref>), following a self-propagating cyclic process the final aim of which is to kill cancer cells. Negative regulators of the tumor-immune cycle by using antibodies against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein1 (PD-1) (<xref ref-type="bibr" rid="B67">67</xref>) ameliorate survival rates of patients suffering from metastatic melanoma (<xref ref-type="bibr" rid="B68">68</xref>). The canonical WNT signaling is responsible for the onset and advancement of many cancers and is a well-established molecular target for cancer therapy (<xref ref-type="bibr" rid="B69">69</xref>–<xref ref-type="bibr" rid="B71">71</xref>). Numerous mutations in genes encoding the canonical WNT pathway have been reported in colorectal cancers presenting mutations of APC and β-catenin genes (<xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B72">72</xref>). Dysfunction of the canonical WNT signaling has been demonstrated in tumor immunology (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>). TCF1 is the endpoint of the canonical WNT signaling (<xref ref-type="fig" rid="F2">Figure 2</xref>) and is a T lymphocyte-specific transcription factor which plays an important role in the development of T cells (<xref ref-type="bibr" rid="B75">75</xref>). TCF1 is involved in maturation and secondary expansion of memory CD8<sup>+</sup> T cells and activates CD8<sup>+</sup> effector T cells (<xref ref-type="bibr" rid="B76">76</xref>).</p>
<p>In cancers, the immune contexture that is partly characterized by the functional orientation of tumor-infiltrating immune cells influences the outcome of patients. Moreover, in metastatic sites, it reflects the corresponding primary cancer (<xref ref-type="bibr" rid="B77">77</xref>). The immune-suppressive mesenchymal stem cells (MSCs) have been shown to be an important source of myofibroblasts <italic>in vivo</italic>. We have recently reported <italic>in vitro</italic> that the immune-suppressive capabilities of MSCs are not altered after their differentiation into myofibroblasts (<xref ref-type="bibr" rid="B78">78</xref>). In MSCs, involvement of the canonical WNT signaling promotes metastatic growth and chemo-resistance of cholangiocarcinoma (<xref ref-type="bibr" rid="B79">79</xref>).</p>
<sec>
<title>WNT/β-Catenin Signaling and Dendritic Cells (DCs)</title>
<p>DCs have tumor antigens on the major histocompatibility complex molecules and prime effector T cells. Antigens are released from cancer cells before encountering DCs, then priming and activation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells follow. Before priming effector T cells, DCs differentiate into CD103<sup>+</sup> DCs that are important for recruitment of effector T cells into tumors (<xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B81">81</xref>). Activating the mutated β-catenin pathway initiates the gene expression of interferon regulatory factor 8 (IRF8) that leads to differentiation and expansion of CD103<sup>+</sup> DCs (<xref ref-type="bibr" rid="B82">82</xref>). Moreover, activation of β-catenin releases CXCL9/10 in CD103<sup>+</sup> DCs and inhibits infiltration of effector T cells (<xref ref-type="bibr" rid="B81">81</xref>).</p>
</sec>
<sec>
<title>WNT/β-Catenin Signaling and CD8<sup>+</sup> T Cells</title>
<p>In the tumor-immune cycle, peripheral naïve CD8<sup>+</sup> T cells differentiate into effector T cells and destroy cancer cells rapidly (<xref ref-type="bibr" rid="B81">81</xref>). CD8<sup>+</sup> T cells are activated and primed by DCs, and then infiltrate tumors to kill cancer cells (<xref ref-type="bibr" rid="B83">83</xref>). During tumor development, cancer cells avoid action of the immune cycle by inhibiting CD8<sup>+</sup> T cell infiltration (<xref ref-type="bibr" rid="B84">84</xref>). Mature naïve CD8<sup>+</sup> T cells are activated by APC and then proliferate in spleen and lymph nodes (<xref ref-type="bibr" rid="B5">5</xref>). Upregulation of the WNT/β-catenin pathway induces apoptosis of mature naïve CD8<sup>+</sup> T cells partially through to the target gene c<italic>-</italic>MYC (<xref ref-type="bibr" rid="B85">85</xref>).</p>
</sec>
<sec>
<title>WNT/β-Catenin Pathway and T Helper (Th) Cells</title>
<p>Th cells are subdivided into Th1, Th2, and Th17 and they help the CD8<sup>+</sup> T cell anti-tumor response through T cell cytokine release (<xref ref-type="bibr" rid="B86">86</xref>). Th cells inhibit cancer cells by activating CD27, CD137, and 4-1BB as well as favoring the synthesis of memory CD8<sup>+</sup> T cells (<xref ref-type="bibr" rid="B87">87</xref>). The WNT/β-catenin signaling plays a role in the development and function of Th cells (<xref ref-type="bibr" rid="B88">88</xref>–<xref ref-type="bibr" rid="B90">90</xref>). It also inhibits Th cells and impairs the anti-tumor immunity. Abnormal WNT/β-catenin pathway impairs the immunity induced by CD4+ T cells. Auto-immune encephalomyelitis activates the canonical WNT pathway that impairs infiltration of CD4<sup>+</sup> T cells. This can be restored by inhibiting the WNT/β-catenin signaling (<xref ref-type="bibr" rid="B90">90</xref>). β-catenin is upregulated in colorectal tumor, and the immunity induced by intra-tumoral CD4<sup>+</sup> T cells is decreased (<xref ref-type="bibr" rid="B89">89</xref>).</p>
</sec>
<sec>
<title>WNT/β-Catenin Signaling and Regulatory T (Treg) Cells</title>
<p>Treg cells support immunosuppression and tolerance to immune stress by inhibiting the effector T (Teff) cell response (<xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B92">92</xref>). The canonical WNT signaling is critical for the Treg cell development and exerts a negative regulation on CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Infiltration of Treg cells into tumors might be due to the inhibition of the anti-tumor immune response. In cancer, down-regulation of the protein kinase CK2, a negative regulator of canonical WNT pathway, inhibits the Treg-mediated immune suppression (<xref ref-type="bibr" rid="B93">93</xref>, <xref ref-type="bibr" rid="B94">94</xref>).</p>
</sec>
<sec>
<title>WNT/β-Catenin Pathway and Tumor Cells</title>
<p>At the last step of the immune cycle, cancer cells are recognized and destroyed by effector T cells. To escape an immune effect, tumor cells express a negative regulatory molecule PD-L1 and generate mutant tumor antigens (<xref ref-type="bibr" rid="B95">95</xref>, <xref ref-type="bibr" rid="B96">96</xref>). cMYC, a target of the canonical WNT pathway binds the promoters of the CD47 and PD-L1 genes. cMYC inhibition ameliorates the anti-tumor response (<xref ref-type="bibr" rid="B97">97</xref>). Upregulation of the WNT/β-catenin signaling in tumor cells induces T cell exclusion and resistance to immunotherapy. Blockade of the canonical WNT signaling decreases the expression of both CD47 and PD-L1 and improves the anti-tumor immune response (<xref ref-type="bibr" rid="B85">85</xref>). In transgenic mouse melanoma, β-catenin stabilization results in a decrease of both T-cell priming and CD8<sup>+</sup> T cell infiltration (<xref ref-type="bibr" rid="B80">80</xref>). Cancer cells remain in a quiescent state after inhibition of the canonical WNT signaling by DKK1 (<xref ref-type="bibr" rid="B98">98</xref>). Although cancer immunotherapy by blocking cancer driver genes can benefit patients (<xref ref-type="bibr" rid="B99">99</xref>–<xref ref-type="bibr" rid="B102">102</xref>), there are several types of resistance to cancer immunotherapy (primary, adaptative, and acquired) (<xref ref-type="bibr" rid="B84">84</xref>). Targeting the canonical WNT pathway could help to overcome the immune-resistance.</p>
</sec>
</sec>
<sec id="s5">
<title>WNT/β-Catenin and TGF-β1 Pathways, Tumor Stroma and Myofibroblasts</title>
<p>The canonical WNT pathway is tightly involved in the development and maintenance of the tumor stroma. The transforming growth factor-β1 (TGF-β1) and myofibroblasts (<xref ref-type="bibr" rid="B103">103</xref>) play a key role in this process. TGF-β1 activates the canonical WNT signaling (<xref ref-type="fig" rid="F3">Figures 3</xref>, <xref ref-type="fig" rid="F6">6</xref>) and induces the differentiation of fibroblasts into myofibroblasts (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B33">33</xref>). Myofibroblasts represent key constituents of the tumor stroma which is active in the cancer development as well as in maintaining the tissue architecture. In cancer stroma, myofibroblasts represent the predominant sub-population of cancer-associated cells (<xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B105">105</xref>). Myofibroblasts, epithelial cells and connective tissue cells provide favorable conditions for tumor invasion, with loss of epithelial properties and transition to epithelial-mesenchymal characteristics (EMT) (<xref ref-type="bibr" rid="B106">106</xref>) that greatly influences the invasive carcinoma advancement and in which the canonical WNT signaling plays a crucial role.</p>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption>
<p>Canonical WNT/β-catenin pathway, Warburg glycolysis, and cancer. Schema of the canonical WNT pathway under aerobic glycolysis in cancer. In the presence of WNT ligands (“on state”), β-catenin accumulates in the cytosol and then translocates to the nucleus to bind TCF-LEF co-transcription factors. This induces the WNT-response gene transcription (CYCLIN D1, cMYC, PDK, MCT-1, fibronectin, etc). Glucose itself activates the canonical WNT pathway. PDK inhibits the PDH complex in mitochondria. Thus, pyruvate cannot be fully converted into acetyl-CoA and cannot enter the TCA cycle. cMYC activates LDH-A which converts cytosolic pyruvate into lactate. MCT-1 favors lactate extrusion out of the cytosol which favors angiogenesis. cMYC increases glutamine entry into both the cytosol and mitochondria. cMYC-induced glutamine enhances aspartate and nucleotide synthesis.</p>
</caption>
<graphic xlink:href="fonc-09-01248-g0006"></graphic>
</fig>
<p>In activated cancer stroma cells, there are neo-formations of contractile stress fibers containing α-smooth muscle actin (α-SMA) and non-muscle myosin (NMMIIA). These cells are named myofibroblasts. In myofibroblasts, there is co-existence of fibroblastic morphological characteristics, such as a well-developed endoplasmic reticulum and α-SMA forming contractile actin microfilament bundles. Proto-myofibroblasts are low contractile cells and when mechanical stress and TGF-β1 are present, they can differentiate into myofibroblasts that express α-SMA and NMMIIA, which are incorporated in stress fibers. This renders myofibroblasts highly contractile (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B107">107</xref>).</p>
<p>In cancers, mechanical and chemical conditions generating myofibroblasts promote the cancer progression. The stromal extracellular matrix (ECM) contains several molecules such as collagen, elastin, fibronectin, hyaluronic acid, proteoglycans, glycoproteins etc. The cancer stroma presents several similarities with skin healing (<xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B109">109</xref>). In cancers, stromal cells become over-activated, proliferate, and upregulate the ECM production. ECM protects growth factors from degradation and can modulate the activity of growth factors and cytokines (<xref ref-type="bibr" rid="B109">109</xref>–<xref ref-type="bibr" rid="B111">111</xref>). The main factors are the fibroblast growth factor, platelet-derived growth factor, tumor necrosis factor, epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor.</p>
<p>Cancer cells release microparticles derived from the plasma which contribute to activate tumor-associated myofibroblasts. Cancer exosomes differentiate fibroblasts into myofibroblasts (<xref ref-type="bibr" rid="B112">112</xref>). In cancers, hyperpermeable vessels allow leakage of proteins from the plasma, fibrinogen and fibronectin into the stroma. Myofibroblasts derive from different precursor cells. EMT represents also a mechanism of myofibroblast generation during tumor development (<xref ref-type="bibr" rid="B113">113</xref>). In the tumor stroma, pericytes could acquire contractile myofibroblast properties (<xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B115">115</xref>). Bone-marrow (BM)-derived MSCs and blood-circulating fibrocytes could be also sources for cancer-associated myofibroblasts. BM-derived cells can differentiate into myofibroblasts in tumor development (<xref ref-type="bibr" rid="B116">116</xref>, <xref ref-type="bibr" rid="B117">117</xref>). MSCs target to the stroma environment of epithelial cancers (<xref ref-type="bibr" rid="B115">115</xref>, <xref ref-type="bibr" rid="B118">118</xref>–<xref ref-type="bibr" rid="B121">121</xref>). In tumor-conditioned medium, BM-MSCs differentiate into myofibroblasts containing α-SMA (<xref ref-type="bibr" rid="B122">122</xref>).</p>
<p>With mechanical stress, TGF-β1, the most important myofibrogenic growth factor, plays a central role in myofibroblast activation and by upregulating the canonical WNT signaling (<xref ref-type="fig" rid="F2">Figures 2</xref>, <xref ref-type="fig" rid="F3">3</xref>). In all circumstances in which TGF-β1 is upregulated, the canonical WNT pathway is overactivated. TGF-β1 is involved in tumor formation (<xref ref-type="bibr" rid="B123">123</xref>) and development (<xref ref-type="bibr" rid="B124">124</xref>–<xref ref-type="bibr" rid="B126">126</xref>). TGF-β1 induces ECM deposition and acts in various epithelial-mesenchymal interactions (<xref ref-type="bibr" rid="B127">127</xref>). Latency and activation of TGF-β1 is regulated by the latent TGF-β1 binding protein-1 (LTBP-1) (<xref ref-type="bibr" rid="B128">128</xref>, <xref ref-type="bibr" rid="B129">129</xref>). In cancers, cells induce proangiogenic effects and favor EMT (<xref ref-type="bibr" rid="B124">124</xref>–<xref ref-type="bibr" rid="B126">126</xref>). TGF-β1 disrupts cell-cell junctions between vascular endothelial cells and favors extravasation of metastasizing cancer cells (<xref ref-type="bibr" rid="B130">130</xref>). In tumor cells, the TGF-β1 blockade decreases metastasis (<xref ref-type="bibr" rid="B131">131</xref>, <xref ref-type="bibr" rid="B132">132</xref>). In the activated tumor stroma, myofibroblasts stimulate the synthesis and activation of TGF-β1 and generate an autocrine forward loop (<xref ref-type="bibr" rid="B133">133</xref>).</p>
<p>TGF-β1 is synthesized together with the latency-associated peptide (LAP) that is cleaved in the cell and linked to TGF-β1. This leads to the small latent complex (SLC) (<xref ref-type="bibr" rid="B134">134</xref>). In compliant low contractile proto-myofibroblasts, TGF-β1, and LAP form the small latent complex (SLC) (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B134">134</xref>). Myofibroblasts secrete SLC which is covalently bound with LTBP-1 (<xref ref-type="bibr" rid="B134">134</xref>, <xref ref-type="bibr" rid="B135">135</xref>). LTBP-1 belongs to the family of the fibrillin proteins and stores the latent TGF-β1 in the ECM. Integrins activate the latent TGF-β1 (<xref ref-type="bibr" rid="B136">136</xref>), which contains RGD for integrin binding in LAP (<xref ref-type="bibr" rid="B137">137</xref>–<xref ref-type="bibr" rid="B139">139</xref>). These mechanisms involve several αv integrins (<xref ref-type="bibr" rid="B140">140</xref>–<xref ref-type="bibr" rid="B142">142</xref>). Myofibroblasts exert a tension on the ECM-stored latent TGF-β1 through integrins. Traction force exerted on SLC induces a conformational change in LAP that releases activated TGF-β1. Stiff ECM favors differentiation into a myofibroblast phenotype (<xref ref-type="bibr" rid="B13">13</xref>) by activating the latent TGF-β1. Tumor-associated stroma is stiffer than the surrounding normal soft connective tissue (<xref ref-type="bibr" rid="B143">143</xref>–<xref ref-type="bibr" rid="B147">147</xref>). Activated cancer-associated fibroblasts produce several growth factors and cytokines that promote tumor progression such as FGF, EGF, TGF-β1, HGF, VEGF, stroma-derived factor-1, and the pro-inflammatory cytokines IL-1, IL-6, IL-8, and CXCL14 (<xref ref-type="bibr" rid="B148">148</xref>–<xref ref-type="bibr" rid="B150">150</xref>). They also provide conditions leading to the tumor progression (<xref ref-type="bibr" rid="B147">147</xref>). Increased stiffness of cancer-associated myofibroblasts modifies epithelial cells toward an invasive and proliferative phenotype.</p>
</sec>
<sec id="s6">
<title>Canonical WNT/β-Catenin Signaling, Warburg Glycolysis, and Cancer</title>
<p>Upregulation of the canonical WNT pathway plays a pivotal role in metabolism and particularly in the aerobic glycolysis (<xref ref-type="fig" rid="F6">Figure 6</xref>). The Warburg effect (<xref ref-type="bibr" rid="B15">15</xref>) denotes that cancer cells, even under aerobic conditions, favor the cytosolic glycolysis pathway rather than mitochondrial phosphorylation. The last product of cytosolic glycolysis is pyruvate, which is then converted into lactate, hence the term “aerobic glycolysis” given to this phenomenon. In terms of ATP production, aerobic glycolysis is much less efficient than mitochondrial oxidative phosphorylation due to the shunt of the tricarboxylic acid (TCA) cycle. In the aerobic glycolysis, one glucose molecule leads to the formation of only 2 ATP molecules, instead of 38 ATP molecules in mitochondrial oxidative phosphorylation. In cancer development, the role of the canonical WNT pathway in metabolism is now better understood (<xref ref-type="bibr" rid="B151">151</xref>, <xref ref-type="bibr" rid="B152">152</xref>). Activation of the canonical WNT signaling via TCF/ LEF induces an activation of the aerobic glycolysis, through upregulation of glycolytic enzymes such as pyruvate dehydrogenase kinase 1 (PDK1), pyruvate kinase M2 (PKM2), lactate dehydrogenase A (LDH-A), monocarboxylate transporter 1 (MCT-1), and glucose transporter (Glut). Activation of PDK1 is required for the Warburg aerobic glycolysis. PDK1 phosphorylates the pyruvate dehydrogenase complex (PDH) which is then inhibited and therefore prevents the conversion of pyruvate into acetyl-CoA in mitochondria, blocking the pyruvate access to oxidative phosphorylation (<xref ref-type="bibr" rid="B153">153</xref>). In this manner, the WNT-driven Warburg metabolism favors the use of glucose for cancer cell proliferation (<xref ref-type="bibr" rid="B22">22</xref>). Upregulation of the canonical WNT pathway leads to β-catenin translocation in the nucleus where β-catenin interacts with TCF/LEF. This results in activation of the β-catenin target genes (PDK1, MTC-1, cMYC, CYCLIN D1, COX- 2, AXIN- 2) (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>) (<xref ref-type="fig" rid="F2">Figures 2</xref>, <xref ref-type="fig" rid="F3">3</xref>, <xref ref-type="fig" rid="F6">6</xref>). Upregulation of the canonical WNT pathway leads to cell proliferation, EMT, migration and angiogenesis (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B154">154</xref>–<xref ref-type="bibr" rid="B156">156</xref>). In various cancers, PDK-1 is upregulated (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B157">157</xref>–<xref ref-type="bibr" rid="B159">159</xref>), so that the pyruvate conversion into acetyl-CoA in mitochondria is decreased and the WNT-driven Warburg aerobic glycolysis induced in spite of the availability of oxygen. In the cytosol, pyruvate is converted into lactate through LDH-A activation. Upregulation of both LDH-A and MCT-1 leads to lactate formation and the secretion of lactate outside of the cell. This induces vascularization (<xref ref-type="bibr" rid="B160">160</xref>) and anabolic production of biomass for nucleotide synthesis (<xref ref-type="bibr" rid="B161">161</xref>, <xref ref-type="bibr" rid="B162">162</xref>). Furthermore, PDK-1 and−2 create conditions conductive to angiogenesis (<xref ref-type="bibr" rid="B163">163</xref>, <xref ref-type="bibr" rid="B164">164</xref>). Inhibition of the canonical WNT signaling decreases the PDK-1 level via the transcription regulation and reduces <italic>in vivo</italic> tumor growth (<xref ref-type="bibr" rid="B22">22</xref>). cMYC, a target gene of β-catenin activates the aerobic glycolysis and glutaminolysis, induces the uptake of glutamine into the cell and mitochondria, activates LDH-A and activates aspartate synthesis that finally leads to nucleotide synthesis (<xref ref-type="bibr" rid="B165">165</xref>, <xref ref-type="bibr" rid="B166">166</xref>). cMYC also stimulates the hypoxia-inducible factor-α (HIF-1α) which in turn regulates PDK-1 (<xref ref-type="bibr" rid="B167">167</xref>). In carcinogenesis, HIF-1α activates the Warburg aerobic glycolysis (<xref ref-type="bibr" rid="B168">168</xref>). In this process, a part of the pyruvate is converted into acetyl-Co-A which enters the TCA cycle, and is converted into citrate. This leads to the synthesis of proteins and lipids. Cellular accumulation of metabolic intermediates such as glycine, aspartate, serine, and ribose, allows <italic>de novo</italic> synthesis of nucleotides (<xref ref-type="fig" rid="F6">Figure 6</xref>), contributing to cell growth and proliferation. Lactate also induces angiogenesis. Importantly, aerobic glycolysis is also induced in response to TGF-β1 (<xref ref-type="bibr" rid="B169">169</xref>) and glucose consumption is increased in cancer cells. High glucose concentration regulates tumor-related processes. Glucose itself directly influences the canonical WNT signaling (<xref ref-type="bibr" rid="B170">170</xref>). High glucose levels enhance the nuclear translocation of β-catenin in response to canonical WNT activation. In cancer cells, glucose-induced β-catenin acetylation increases canonical WNT signaling. Stimulation of the canonical WNT pathway leads to activation of HIF-1α causing metabolic remodeling (<xref ref-type="bibr" rid="B154">154</xref>, <xref ref-type="bibr" rid="B171">171</xref>) and accentuates the Warburg effect. Thus, cancer cells use the Warburg effect at all oxygen levels (<xref ref-type="bibr" rid="B172">172</xref>). The increase in lactate production and the activation of HIF-1α by the upregulated canonical WNT signaling are associated with the increase of angiogenesis and poor prognosis of cancers (<xref ref-type="bibr" rid="B173">173</xref>). Lactate released from cancer cells, via the MCT-1 transporter allows entry of lactate anion into cancer endothelial cells. In normoxic endothelial cells, lactate activates HIF-1α in a positive feedback loop by blocking HIF-1α prolyl hydroxylation and then prevents HIF labeling by the von Hippel-Lindau protein (<xref ref-type="bibr" rid="B163">163</xref>, <xref ref-type="bibr" rid="B173">173</xref>, <xref ref-type="bibr" rid="B174">174</xref>).</p>
<p>Lactate released from the cell initiates a transformation of the microenvironment independently of hypoxia. This enables angiogenesis and activation of the NF-kappaB pathway and prevents cell death through antiapoptotic proteins facilitating survival of cancer cells in a hostile environment (<xref ref-type="bibr" rid="B175">175</xref>). Knockdown of PDK-1 reverts the Warburg phenotype, diminishes the normoxic HIF-1α expression, hypoxic cell survival, invasion, and inhibits cancer development. Glycolysis metabolites due to high PDK-1 expression may promote HIF-1α activation. This sustains a feed-forward loop for cancer development. If corrected, these metabolic abnormalities may represent new cancer therapies which can synergize with other cancer treatments.</p>
<sec>
<title>PI3K-AKT Pathway in WNT-Driven Aerobic Glycolysis and Cancer</title>
<p>The serine/threonine kinase AKT or protein kinase B (PKB) is often stimulated in human cancers (<xref ref-type="bibr" rid="B176">176</xref>). AKT activation constitutes a hallmark of the Warburg effect in most cancers. In tumor cells, hyperactivation of phosphatidyl-inositol 3-kinase (PI3K)-protein kinase B (AKT) signaling is associated with an augmented rate of glucose metabolism. AKT is activated by PIP3. PI3K synthesizes phosphatidylinositol-3,4,5-triphosphate (PIP3) from PIP2. The PI3K-AKT signaling induces cell growth and proliferation, cell migration, and angiogenesis. This signaling is induced by the linking of extracellular ligands to a receptor tyrosine kinase (RTK) in the plasma membrane (<xref ref-type="fig" rid="F6">Figure 6</xref>) and is upregulated in several cancers. The AKT signaling activates the canonical WNT pathway by decreasing the GSK-3β activity (inactive form: pGSK-3β). AKT activation increases the Warburg aerobic glycolysis in cancer. AKT increases the ATP production and enhances glycolytic metabolism by several mechanisms. It increases glucose uptake by increasing the Glu transporter expression. AKT activates mTORC1, which promotes HIF-1α under normoxic conditions and increases LDH activity. The PI3K-AKT signaling increases the hypoxia-inducible transcription factor (<xref ref-type="bibr" rid="B177">177</xref>). AKT phosphorylates and stimulates phosphofructokinase-2 (PFK2), which in turn induces activation of the phosphofructokinase-1 (PFK1) by the PFK2 product fructose-2,6-bisphosphate (Fru-2,6-P2), an activator of PFK1. PFK1 is an allosteric enzyme responsible for glycolytic oscillations and can lead to instability beyond which a new state can be created in time and in space. These oscillations are dissipative structures initially described by Goldbeter and Lefever (<xref ref-type="bibr" rid="B178">178</xref>) and behave far-from-equilibrium (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B179">179</xref>, <xref ref-type="bibr" rid="B180">180</xref>). Increase in activity of PFK-1 is characteristic of tumor cells and is induced by oncogenes.</p>
<p>Upregulation of the PI3K-AKT signaling is frequently associated with cancers, such as glioblastomas, breast, pancreatic, and ovarian cancers (<xref ref-type="bibr" rid="B181">181</xref>). AKT mRNA is increased in breast and prostate cancers. PI3K-AKT induces angiogenesis by activating VEGF in endothelial cells and acting on the endothelial nitric oxide synthase. This stimulates vasodilation and vascular remodeling (<xref ref-type="bibr" rid="B182">182</xref>). The PI3K-AKT pathway is inhibited by the phosphatase and tensin homolog (PTEN) (<xref ref-type="bibr" rid="B183">183</xref>) (<xref ref-type="fig" rid="F6">Figure 6</xref>). PTEN is a PIP3-phosphatase and inhibits PI3K. As PI3K-AKT is a key signaling activated in cancer, PTEN appears to be an interesting target against the tumor progression.</p>
</sec>
<sec>
<title>Reverse Warburg Effect</title>
<p>The Warburg effect does not take into account the metabolic interactions between cancer cells and the microenvironment (<xref ref-type="bibr" rid="B184">184</xref>, <xref ref-type="bibr" rid="B185">185</xref>). The reverse Warburg effect (<xref ref-type="bibr" rid="B186">186</xref>) is a new metabolic process describing interacting between cancer cells and neighboring cancer-associated fibroblasts (CAFs) or stroma cells (<xref ref-type="bibr" rid="B187">187</xref>). In several human tumor cells, aerobic glycolysis contributes &lt;50% for energy production (<xref ref-type="bibr" rid="B188">188</xref>–<xref ref-type="bibr" rid="B191">191</xref>) and some cancer cells exhibit high rates of the mitochondrial oxidative phosphorylation system (OXPHOs) (<xref ref-type="bibr" rid="B192">192</xref>–<xref ref-type="bibr" rid="B194">194</xref>). Thus, OXPHOs and aerobic glycolysis are not always mutually exclusive. Heterogeneous cancer cells can show various metabolic phenotypes (<xref ref-type="bibr" rid="B195">195</xref>–<xref ref-type="bibr" rid="B198">198</xref>). The OXPHOs metabolic pathway does not invalidate the Warburg effect but rather exhibits the complex plasticity of cancer metabolism and is involved in proliferation, metastasis, angiogenesis, and drug resistance in cancer cells. Oxidative stress in the two-compartment metabolic coupling and variations in cellular electromagnetic field could initiate the reverse Warburg effect. Cancer cells secrete ROSs in the microenvironment, which induces oxidative stress in CAFs which is strongly correlated to the reverse Warburg effect. Oxidative stress mechanism drives CAFs-cancer cells metabolic coupling and favors tumor growth via genetic and metabolic mechanisms. Oxidative stress related loss of stromal caveolin-1 (Cav-1) increases the production of ROSs in tumor cells, which initiates the cascade of oxidative stress in CAFs via a positive feedback mechanism (<xref ref-type="bibr" rid="B187">187</xref>, <xref ref-type="bibr" rid="B199">199</xref>, <xref ref-type="bibr" rid="B200">200</xref>) and plays a role in cancer proliferation, recurrence and prognosis (<xref ref-type="bibr" rid="B201">201</xref>, <xref ref-type="bibr" rid="B202">202</xref>). Although the reverse Warburg effect and the role of the canonical WNT signaling on the reverse Warburg effect are not totally understood to-day, in the future they could represent a new approach for cancer treatment.</p>
</sec>
</sec>
<sec id="s7">
<title>Canonical WNT Signaling, Circadian Rhythms (CRs), and Cancer</title>
<p>CRs are endogenous rhythms that last ~24 h, due to a negative feedback produced by a protein acting on the expression of its own gene (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B203">203</xref>, <xref ref-type="bibr" rid="B204">204</xref>). In mammals, CRs involve several major factors such as brain and muscle aryl-hydrocarbon receptor nuclear translocator-like1 (BMAL1), circadian locomotor output cycles kaput (CLOCK), period 1 (PER1), period 2 (PER2), and period 3 (PER3) (<xref ref-type="bibr" rid="B205">205</xref>, <xref ref-type="bibr" rid="B206">206</xref>). CRs are involved in hormone secretion, heart rate and blood pressure, sleep-awake, feeding patterns, energy metabolism, and body temperature. Importantly, disruption of CRs appears linked to cancer, leading to aberrant cellular proliferation and involving the canonical WNT signaling (<xref ref-type="bibr" rid="B23">23</xref>). Due to several connections between cellular metabolism and the circadian clock, abnormal metabolism described in cancers may be a consequence of disrupted CRs (<xref ref-type="bibr" rid="B207">207</xref>). A decreased BMAL1 activity changes the behavior of genes involved in the canonical WNT pathway (<xref ref-type="bibr" rid="B208">208</xref>). β-catenin induces PER2 degradation modifying the circadian clock gene expression in intestinal mucosa of ApcMin/+ mice (<xref ref-type="bibr" rid="B209">209</xref>). A deceased expression of PER1 and/or PER2 has been reported in numerous cancers: breast tumor (<xref ref-type="bibr" rid="B210">210</xref>), prostate tumor (<xref ref-type="bibr" rid="B211">211</xref>), pancreatic tumor (<xref ref-type="bibr" rid="B212">212</xref>), colorectal tumor (<xref ref-type="bibr" rid="B213">213</xref>), chronic myeloid leukemia (<xref ref-type="bibr" rid="B214">214</xref>), glioma (<xref ref-type="bibr" rid="B215">215</xref>, <xref ref-type="bibr" rid="B216">216</xref>), and intestinal epithelial neoplastic transformation (<xref ref-type="bibr" rid="B209">209</xref>).</p>
<p>From a thermodynamic viewpoint, CRs operate far from equilibrium and are dissipative structures (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B217">217</xref>). By applying Schrödinger's concepts to the modern thermodynamics of physical, chemical and biological systems that behave far from equilibrium, Prigogine and his colleagues opened a new understanding for the description of dissipative structures which occupy a key role in the world of living beings. Cancers are exergonic processes in which heat flows from the cancer to its surroundings (<xref ref-type="bibr" rid="B218">218</xref>). In cancer cells, the entropy production rate increases and characterizes irreversible processes driven by changes in thermodynamics properties (<xref ref-type="bibr" rid="B61">61</xref>).</p>
</sec>
<sec id="s8">
<title>Canonical WNT Signaling, Inflammation, Fibrosis, and Cancer</title>
<sec>
<title>Inflammation</title>
<p>Chronic inflammation contributes to cancer development (<xref ref-type="bibr" rid="B219">219</xref>, <xref ref-type="bibr" rid="B220">220</xref>). The role of prostaglandin E2 (PGE2) by stimulating the canonical WNT pathway has been well-established. The crosstalk between PGE2 and the canonical WNT signaling indicates that chronic inflammation caused by a prolonged increase of PGE2 may upregulate the canonical WNT signaling leading to cell proliferation and cancer. PGE2 favors the transcription of β-catenin (<xref ref-type="bibr" rid="B221">221</xref>, <xref ref-type="bibr" rid="B222">222</xref>) and leads to growth of cancer cells such as in colon cancer. Non-steroidal anti-inflammatory drugs (NSAIDs) improve the treatment of colorectal cancer (<xref ref-type="bibr" rid="B223">223</xref>), partly due to interference with the β-catenin signaling and by inhibiting the PGE2 synthesis. PGE2 regulates the canonical WNT activity of hematopoietic stem cells (HSCs) in the zebrafish. Inhibition of PGE2 synthesis blocks the WNT-induced alterations in HSCs. PGE2 alters the β-catenin degradation via the cAMP/PKA signaling. In stem cells, WNT upregulation requires PGE2 (<xref ref-type="bibr" rid="B224">224</xref>). Dimethyl-prostaglandin E2 increases HSCs <italic>in vivo</italic> and increases the canonical WNT pathway activity (<xref ref-type="bibr" rid="B225">225</xref>). Conversely the canonical WNT signaling activates interleukins (IL)-7R and IL-2Rβ. In neuroectodermal stem cells, PGE2 interacts with the canonical WNT pathway partly through PKA and PI3K (<xref ref-type="bibr" rid="B226">226</xref>). PGE2 upregulates several WNT-target genes such as Ctnnb1, Ptgs2, Ccnd1, Mmp9.</p>
</sec>
<sec>
<title>Cancer and Fibrosis: A Similar Pathway</title>
<p>Several intracellular processes involved in cancers are similar to those encountered in fibrosis, and particularly an activation of the canonical WNT /TGF-β1 signaling (<xref ref-type="bibr" rid="B227">227</xref>). Similarly to that observed in cancer stroma, activation of this pathway leads to differentiation of fibroblasts into myofibroblasts. In cancer (mammary carcinoma, epithelial cells in tumor mammary glands), fibrotic lesions (nodules of Dupuytrens, hypertrophic scars) (<xref ref-type="bibr" rid="B228">228</xref>), and normal placental stem villi (<xref ref-type="bibr" rid="B229">229</xref>), the main myosin molecular motor in myofibroblasts is the non-muscle myosin IIA (NMMIIA). Contractile NMMIIA kinetics are particularly slow (<xref ref-type="bibr" rid="B230">230</xref>) and their entropy production rate is dramatically low (<xref ref-type="bibr" rid="B231">231</xref>). These contractile myofibroblasts allow skin retraction in wound healing (<xref ref-type="bibr" rid="B232">232</xref>–<xref ref-type="bibr" rid="B234">234</xref>). Patients suffering of cancer often receive a therapy by external ionizing radiations that leads to damages in both tumor cells and health tissues. Radiations induce numerous skin changes including inflammation and late radiation-induced fibrosis (RIF). RIF are characterized by fibroblast proliferation and myofibroblast differentiation, DNA damage, inflammation by stimulation of the NF-kappaB pathway (<xref ref-type="bibr" rid="B32">32</xref>). The over-expression of TGF-β1 and the upregulated canonical WNT signaling are involved in the molecular mechanism underlying the RIF.</p>
</sec>
</sec>
<sec id="s9">
<title>Conclusions and Perspectives</title>
<p>It is currently well-demonstrated that the canonical WNT signaling intervenes at every stages in development of many cancers. When activated, this signaling induces and initiates several periodic or oscillating phenomena, such as the cell division cycle, the immune cycle, numerous circadian rhythms, and phosphofructokinase oscillations that are dissipative structures. This is because β-catenin modifies the expression of a considerable number of genes involved in one or others of these decisive areas of the cancer pathogeny. Thus, CYCLIN D1 and cMYC influence the cell division cycle. TGF-β1 also plays an important role activating the canonical WNT signaling directly or indirectly, and by acting on both the PI3K-AKT and GSK-3β pathways. Activation of the canonical WNT signaling affects many enzymes or transporters, resulting in Warburg glycolysis, which diverts pyruvate metabolism to lactate, a useful pathway for protein synthesis in tumor cells. All these different functions of the canonical WNT give it an eminent status as target immunotherapies against cancer.</p>
</sec>
<sec id="s10">
<title>Author Contributions</title>
<p>All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p>
<sec>
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>We would like to thank Dr. Christophe Locher, Director of the Clinical Research Center, Grand Hôpital de l'Est Francilien (GHEF), Meaux, France and Mr. Vincent Gobert, Administrative Manager of the Clinical Research Center, Meaux, France. Prof. Brian Keogh has substantially improved the English language in the manuscript.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding</bold>. The authors thank the Grand Hôpital de l'Est Francilien (GHEF) for its valuable support in making the necessary research facilities available for this study.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>Varmus</surname><given-names>HE</given-names></name></person-group>. <article-title>Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome</article-title>. <source/>Cell. (<year>1982</year>) <volume>31</volume>:<fpage>99</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(82)90409-3</pub-id><pub-id pub-id-type="pmid">6297757</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>AW</given-names></name></person-group>. <article-title>Cyclin synthesis and degradation and the embryonic cell cycle</article-title>. <source/>J Cell Sci Suppl. (<year>1989</year>) <volume>12</volume>:<fpage>65</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.1989.Supplement_12.7</pub-id><pub-id pub-id-type="pmid">2534557</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>AW</given-names></name></person-group>. <article-title>Cell biology: the cell cycle as a cdc2 cycle</article-title>. <source/>Nature. (<year>1989</year>) <volume>342</volume>:<fpage>14</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/342014a0</pub-id><pub-id pub-id-type="pmid">2535628</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurse</surname><given-names>P</given-names></name></person-group>. <article-title>Cyclin dependent kinases and cell cycle control (nobel lecture)</article-title>. <source/>Chembiochem. (<year>2002</year>) <volume>3</volume>:<fpage>596</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1002/1439-7633(20020703)3:7&lt;596::AID-CBIC596&gt;3.0.CO;2-U</pub-id><pub-id pub-id-type="pmid">12324993</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name></person-group>. <article-title>Oncology meets immunology: the cancer-immunity cycle</article-title>. <source/>Immunity. (<year>2013</year>) <volume>39</volume>:<fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.012</pub-id><pub-id pub-id-type="pmid">23890059</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savvidis</surname><given-names>C</given-names></name><name><surname>Koutsilieris</surname><given-names>M</given-names></name></person-group>. <article-title>Circadian rhythm disruption in cancer biology</article-title>. <source/>Mol Med. (<year>2012</year>) <volume>18</volume>:<fpage>1249</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.2119/molmed.2012.00077</pub-id><pub-id pub-id-type="pmid">22811066</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>TC</given-names></name><name><surname>Sparks</surname><given-names>AB</given-names></name><name><surname>Rago</surname><given-names>C</given-names></name><name><surname>Hermeking</surname><given-names>H</given-names></name><name><surname>Zawel</surname><given-names>L</given-names></name><name><surname>da Costa</surname><given-names>LT</given-names></name><etal></etal></person-group>. <article-title>Identification of c-MYC as a target of the APC pathway</article-title>. <source/>Science. (<year>1998</year>) <volume>281</volume>:<fpage>1509</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1126/science.281.5382.1509</pub-id><pub-id pub-id-type="pmid">9727977</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shtutman</surname><given-names>M</given-names></name><name><surname>Zhurinsky</surname><given-names>J</given-names></name><name><surname>Simcha</surname><given-names>I</given-names></name><name><surname>Albanese</surname><given-names>C</given-names></name><name><surname>D'Amico</surname><given-names>M</given-names></name><name><surname>Pestell</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway</article-title>. <source/>Proc Natl Acad Sci USA. (<year>1999</year>) <volume>96</volume>:<fpage>5522</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.96.10.5522</pub-id><pub-id pub-id-type="pmid">10318916</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tetsu</surname><given-names>O</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group>. <article-title>Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells</article-title>. <source/>Nature. (<year>1999</year>) <volume>398</volume>:<fpage>422</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/18884</pub-id><pub-id pub-id-type="pmid">10201372</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niehrs</surname><given-names>C</given-names></name><name><surname>Acebron</surname><given-names>SP</given-names></name></person-group>. <article-title>Mitotic and mitogenic Wnt signalling</article-title>. <source/>EMBO J. (<year>2012</year>) <volume>31</volume>:<fpage>2705</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2012.124</pub-id><pub-id pub-id-type="pmid">22617425</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name></person-group>. <article-title>Wnt/beta-catenin signaling in development and disease</article-title>. <source/>Cell. (<year>2006</year>) <volume>127</volume>:<fpage>469</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2006.10.018</pub-id><pub-id pub-id-type="pmid">17081971</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Tian</surname><given-names>T</given-names></name><name><surname>Kalland</surname><given-names>KH</given-names></name><name><surname>Ke</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name></person-group>. <article-title>Targeting Wnt/β-catenin signaling for cancer immunotherapy</article-title>. <source/>Trends Pharmacol Sci. (<year>2018</year>) <volume>39</volume>:<fpage>648</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2018.03.008</pub-id><pub-id pub-id-type="pmid">29678298</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinz</surname><given-names>B</given-names></name></person-group>. <article-title>The myofibroblast: paradigm for a mechanically active cell</article-title>. <source/>J Biomech. (<year>2010</year>) <volume>43</volume>:<fpage>146</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbiomech.2009.09.020</pub-id><pub-id pub-id-type="pmid">19800625</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otranto</surname><given-names>M</given-names></name><name><surname>Sarrazy</surname><given-names>V</given-names></name><name><surname>Bonte</surname><given-names>F</given-names></name><name><surname>Hinz</surname><given-names>B</given-names></name><name><surname>Gabbiani</surname><given-names>G</given-names></name><name><surname>Desmouliere</surname><given-names>A</given-names></name></person-group>. <article-title>The role of the myofibroblast in tumor stroma remodeling</article-title>. <source/>Cell Adhes Migrat. (<year>2012</year>) <volume>6</volume>:<fpage>203</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.4161/cam.20377</pub-id><pub-id pub-id-type="pmid">22568985</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warburg</surname><given-names>O</given-names></name></person-group>. <article-title>On the origin of cancer cells</article-title>. <source/>Science. (<year>1956</year>) <volume>123</volume>:<fpage>309</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1126/science.123.3191.309</pub-id><pub-id pub-id-type="pmid">13298683</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldbeter</surname><given-names>A</given-names></name></person-group>. <article-title>Mechanism for oscillatory synthesis of cyclic AMP in <italic>Dictyostelium discoideum</italic></article-title>. <source/>Nature. (<year>1975</year>) <volume>253</volume>:<fpage>540</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1038/253540a0</pub-id><pub-id pub-id-type="pmid">163974</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Bowerman</surname><given-names>B</given-names></name><name><surname>Boutros</surname><given-names>M</given-names></name><name><surname>Perrimon</surname><given-names>N</given-names></name></person-group>. <article-title>The promise and perils of Wnt signaling through beta-catenin</article-title>. <source/>Science. (<year>2002</year>) <volume>296</volume>:<fpage>1644</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1126/science.1071549</pub-id><pub-id pub-id-type="pmid">12040179</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Kohn</surname><given-names>AD</given-names></name><name><surname>De Ferrari</surname><given-names>GV</given-names></name><name><surname>Kaykas</surname><given-names>A</given-names></name></person-group>. <article-title>WNT and beta-catenin signalling: diseases and therapies</article-title>. <source/>Nat Rev Genet. (<year>2004</year>) <volume>5</volume>:<fpage>691</fpage>–<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1038/nrg1427</pub-id><pub-id pub-id-type="pmid">15372092</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name></person-group>. <article-title>Wnt signaling in disease and in development</article-title>. <source/>Cell Res. (<year>2005</year>) <volume>15</volume>:<fpage>28</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cr.7290260</pub-id><pub-id pub-id-type="pmid">15686623</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name></person-group>. <article-title>Wnt/β-catenin signaling and disease</article-title>. <source/>Cell. (<year>2012</year>) <volume>149</volume>:<fpage>1192</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.05.012</pub-id><pub-id pub-id-type="pmid">22682243</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angers</surname><given-names>S</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group>. <article-title>Proximal events in Wnt signal transduction</article-title>. <source/>Nat Rev Mol Cell Biol. (<year>2009</year>) <volume>10</volume>:<fpage>468</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2717</pub-id><pub-id pub-id-type="pmid">19536106</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pate</surname><given-names>KT</given-names></name><name><surname>Stringari</surname><given-names>C</given-names></name><name><surname>Sprowl-Tanio</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>TeSlaa</surname><given-names>T</given-names></name><name><surname>Hoverter</surname><given-names>NP</given-names></name><etal></etal></person-group>. <article-title>Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer</article-title>. <source/>EMBO J. (<year>2014</year>) <volume>33</volume>:<fpage>1454</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.15252/embj.201488598</pub-id><pub-id pub-id-type="pmid">24825347</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y</given-names></name><name><surname>Claes</surname><given-names>V</given-names></name><name><surname>Duthoit</surname><given-names>G</given-names></name><name><surname>Hebert</surname><given-names>JL</given-names></name></person-group>
<article-title>Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction</article-title>. <source/>Front Physiol. (<year>2014</year>) <volume>5</volume>:<fpage>429</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2014.00429</pub-id><pub-id pub-id-type="pmid">25414671</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerhold</surname><given-names>DL</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists</article-title>. <source/>Endocrinology. (<year>2002</year>) <volume>143</volume>:<fpage>2106</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1210/endo.143.6.8842</pub-id><pub-id pub-id-type="pmid">12021175</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girnun</surname><given-names>GD</given-names></name><name><surname>Domann</surname><given-names>FE</given-names></name><name><surname>Moore</surname><given-names>SA</given-names></name><name><surname>Robbins</surname><given-names>ME</given-names></name></person-group>. <article-title>Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter</article-title>. <source/>Mol Endocrinol. (<year>2002</year>) <volume>16</volume>:<fpage>2793</fpage>–<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1210/me.2002-0020</pub-id><pub-id pub-id-type="pmid">12456800</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takada</surname><given-names>I</given-names></name><name><surname>Kouzmenko</surname><given-names>AP</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name></person-group>. <article-title>Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis</article-title>. <source/>Nat Rev Rheumatol. (<year>2009</year>) <volume>5</volume>:<fpage>442</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2009.137</pub-id><pub-id pub-id-type="pmid">19581903</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Carson</surname><given-names>DA</given-names></name></person-group>. <article-title>Repression of β-catenin signaling by PPAR γ ligands</article-title>. <source/>Eur J Pharmacol. (<year>2010</year>) <volume>636</volume>:<fpage>198</fpage>–<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2010.03.010</pub-id><pub-id pub-id-type="pmid">20303941</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Farmer</surname><given-names>SR</given-names></name></person-group>. <article-title>Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin</article-title>. <source/>Mol Cell Biol. (<year>2006</year>) <volume>26</volume>:<fpage>5827</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.00441-06</pub-id><pub-id pub-id-type="pmid">16847334</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djouadi</surname><given-names>F</given-names></name><name><surname>Lecarpentier</surname><given-names>Y</given-names></name><name><surname>Hebert</surname><given-names>JL</given-names></name><name><surname>Charron</surname><given-names>P</given-names></name><name><surname>Bastin</surname><given-names>J</given-names></name><name><surname>Coirault</surname><given-names>C</given-names></name></person-group>
<article-title>A potential link between PPAR signaling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy (ARVC)</article-title>. <source/>Cardiovasc Res. (<year>2009</year>) <volume>84</volume>:<fpage>83</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvp183</pub-id><pub-id pub-id-type="pmid">19497962</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y</given-names></name><name><surname>Claes</surname><given-names>V</given-names></name><name><surname>Vallee</surname><given-names>A</given-names></name><name><surname>Hebert</surname><given-names>JL</given-names></name></person-group>. <article-title>Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical WNT/beta-catenin pathway</article-title>. <source/>Clin Transl Med. (<year>2017</year>) <volume>6</volume>:<fpage>14</fpage>. <pub-id pub-id-type="doi">10.1186/s40169-017-0144-7</pub-id><pub-id pub-id-type="pmid">28405929</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallee</surname><given-names>A</given-names></name><name><surname>Lecarpentier</surname><given-names>Y</given-names></name></person-group>. <article-title>Crosstalk between peroxisome proliferator-activated receptor gamma and the canonical WNT/beta-catenin pathway in chronic inflammation and oxidative stress during carcinogenesis</article-title>. <source/>Front Immunol. (<year>2018</year>) <volume>9</volume>:<fpage>745</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00745</pub-id><pub-id pub-id-type="pmid">29706964</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallee</surname><given-names>A</given-names></name><name><surname>Lecarpentier</surname><given-names>Y</given-names></name><name><surname>Guillevin</surname><given-names>R</given-names></name><name><surname>Vallee</surname><given-names>JN</given-names></name></person-group>. <article-title>Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR gamma in radiation-induced fibrosis</article-title>. <source/>Oncotarget. (<year>2017</year>) <volume>8</volume>:<fpage>90579</fpage>–<lpage>604</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.21234</pub-id><pub-id pub-id-type="pmid">29163854</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y</given-names></name><name><surname>Schussler</surname><given-names>O</given-names></name><name><surname>Claes</surname><given-names>V</given-names></name><name><surname>Vallée</surname><given-names>A</given-names></name></person-group>
<article-title>The myofibroblast: TGFβ-1, a conductor which plays a key role in fibrosis by regulating the balance between PPARγ and the canonical WNT Pathway</article-title>. <source/>Nucl Recep Res. (<year>2017</year>) <volume>4</volume>:<fpage>101299</fpage>
<pub-id pub-id-type="doi">10.11131/2017/101299</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Ahmad</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Early stimulation and late inhibition of peroxisome proliferator-activated receptor gamma (PPAR gamma) gene expression by transforming growth factor beta in human aortic smooth muscle cells: role of early growth-response factor-1 (Egr-1), activator protein 1 (AP1) and Smads</article-title>. <source/>Biochem J. (<year>2003</year>) <volume>370</volume>(Pt 3):<fpage>1019</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1042/bj20021503</pub-id><pub-id pub-id-type="pmid">12457461</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>SH</given-names></name></person-group>. <article-title>The myofibroblast in pulmonary fibrosis</article-title>. <source/>Chest. (<year>2002</year>) <volume>122</volume>(<issue>6 Suppl</issue>.):<fpage>286S</fpage>−<lpage>9S</lpage>. <pub-id pub-id-type="doi">10.1378/chest.122.6_suppl.286S</pub-id><pub-id pub-id-type="pmid">12475801</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Rekhter</surname><given-names>MD</given-names></name><name><surname>Gordon</surname><given-names>D</given-names></name><name><surname>Phan</surname><given-names>SH</given-names></name></person-group>. <article-title>Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study</article-title>. <source/>Am J Pathol. (<year>1994</year>) <volume>145</volume>:<fpage>114</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="pmid">7518191</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughan</surname><given-names>MB</given-names></name><name><surname>Howard</surname><given-names>EW</given-names></name><name><surname>Tomasek</surname><given-names>JJ</given-names></name></person-group>. <article-title>Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast</article-title>. <source/>Exp Cell Res. (<year>2000</year>) <volume>257</volume>:<fpage>180</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1006/excr.2000.4869</pub-id><pub-id pub-id-type="pmid">10854066</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>BC</given-names></name><name><surname>Liebler</surname><given-names>JM</given-names></name><name><surname>Luby-Phelps</surname><given-names>K</given-names></name><name><surname>Nicholson</surname><given-names>AG</given-names></name><name><surname>Crandall</surname><given-names>ED</given-names></name><name><surname>du Bois</surname><given-names>RM</given-names></name><etal></etal></person-group>. <article-title>Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis</article-title>. <source/>Am J Pathol. (<year>2005</year>) <volume>166</volume>:<fpage>1321</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)62351-6</pub-id><pub-id pub-id-type="pmid">15855634</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KK</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Szekeres</surname><given-names>C</given-names></name><name><surname>Kugler</surname><given-names>MC</given-names></name><name><surname>Wolters</surname><given-names>PJ</given-names></name><name><surname>Hill</surname><given-names>ML</given-names></name><etal></etal></person-group>. <article-title>Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis</article-title>. <source/>J Clin Invest. (<year>2009</year>) <volume>119</volume>:<fpage>213</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1172/JCI36940</pub-id><pub-id pub-id-type="pmid">19104148</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>BC</given-names></name><name><surname>Borok</surname><given-names>Z</given-names></name></person-group>. <article-title>TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease</article-title>. <source/>Am J Physiol Lung Cell Mol Physiol. (<year>2007</year>) <volume>293</volume>:<fpage>L525</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00163.2007</pub-id><pub-id pub-id-type="pmid">17631612</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>BC</given-names></name><name><surname>duBois</surname><given-names>RM</given-names></name><name><surname>Borok</surname><given-names>Z</given-names></name></person-group>. <article-title>Epithelial origin of myofibroblasts during fibrosis in the lung</article-title>. <source/>Proc Am Thorac Soc. (<year>2006</year>) <volume>3</volume>:<fpage>377</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1513/pats.200601-004TK</pub-id><pub-id pub-id-type="pmid">16738204</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldmann</surname><given-names>T</given-names></name><name><surname>Zissel</surname><given-names>G</given-names></name><name><surname>Watz</surname><given-names>H</given-names></name><name><surname>Dromann</surname><given-names>D</given-names></name><name><surname>Reck</surname><given-names>M</given-names></name><name><surname>Kugler</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Human alveolar epithelial cells type II are capable of TGFbeta-dependent epithelial-mesenchymal-transition and collagen-synthesis</article-title>. <source/>Respir Res. (<year>2018</year>) <volume>19</volume>:<fpage>138</fpage>. <pub-id pub-id-type="doi">10.1186/s12931-018-0841-9</pub-id><pub-id pub-id-type="pmid">30041633</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massague</surname><given-names>J</given-names></name></person-group>. <article-title>G1 cell-cycle control and cancer</article-title>. <source/>Nature. (<year>2004</year>) <volume>432</volume>:<fpage>298</fpage>–<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1038/nature03094</pub-id><pub-id pub-id-type="pmid">15549091</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osthus</surname><given-names>RC</given-names></name><name><surname>Shim</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Reddy</surname><given-names>R</given-names></name><name><surname>Mukherjee</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc</article-title>. <source/>J Biol Chem. (<year>2000</year>) <volume>275</volume>:<fpage>21797</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.C000023200</pub-id><pub-id pub-id-type="pmid">10823814</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Sancho</surname><given-names>E</given-names></name><name><surname>Verweij</surname><given-names>C</given-names></name><name><surname>de Lau</surname><given-names>W</given-names></name><name><surname>Oving</surname><given-names>I</given-names></name><name><surname>Hurlstone</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells</article-title>. <source/>Cell. (<year>2002</year>) <volume>111</volume>:<fpage>241</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(02)01014-0</pub-id><pub-id pub-id-type="pmid">12408868</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name></person-group>. <article-title>Wnt signaling and stem cell control</article-title>. <source/>Cell Res. (<year>2008</year>) <volume>18</volume>:<fpage>523</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2008.47</pub-id><pub-id pub-id-type="pmid">18392048</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daksis</surname><given-names>JI</given-names></name><name><surname>Lu</surname><given-names>RY</given-names></name><name><surname>Facchini</surname><given-names>LM</given-names></name><name><surname>Marhin</surname><given-names>WW</given-names></name><name><surname>Penn</surname><given-names>LJ</given-names></name></person-group>. <article-title>Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle</article-title>. <source/>Oncogene. (<year>1994</year>) <volume>9</volume>:<fpage>3635</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="pmid">7526316</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diehl</surname><given-names>JA</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group>. <article-title>Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization</article-title>. <source/>Genes Dev. (<year>1998</year>) <volume>12</volume>:<fpage>3499</fpage>–<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1101/gad.12.22.3499</pub-id><pub-id pub-id-type="pmid">9832503</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welcker</surname><given-names>M</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Loeb</surname><given-names>KR</given-names></name><name><surname>Grim</surname><given-names>J</given-names></name><name><surname>Bloecher</surname><given-names>A</given-names></name><name><surname>Gurien-West</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation</article-title>. <source/>Mol Cell. (<year>2003</year>) <volume>12</volume>:<fpage>381</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/S1097-2765(03)00287-9</pub-id><pub-id pub-id-type="pmid">14536078</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welcker</surname><given-names>M</given-names></name><name><surname>Orian</surname><given-names>A</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Grim</surname><given-names>JE</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name><name><surname>Eisenman</surname><given-names>RN</given-names></name><etal></etal></person-group>. <article-title>The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2004</year>) <volume>101</volume>:<fpage>9085</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0402770101</pub-id><pub-id pub-id-type="pmid">15150404</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alao</surname><given-names>JP</given-names></name></person-group>. <article-title>The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention</article-title>. <source/>Mol Cancer. (<year>2007</year>) <volume>6</volume>:<fpage>24</fpage>. <pub-id pub-id-type="doi">10.1186/1476-4598-6-24</pub-id><pub-id pub-id-type="pmid">17407548</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassanian</surname><given-names>SM</given-names></name><name><surname>Ardeshirylajimi</surname><given-names>A</given-names></name><name><surname>Dinarvand</surname><given-names>P</given-names></name><name><surname>Rezaie</surname><given-names>AR</given-names></name></person-group>. <article-title>Inorganic polyphosphate promotes cyclin D1 synthesis through activation of mTOR/Wnt/beta-catenin signaling in endothelial cells</article-title>. <source/>J Thromb Haemos. (<year>2016</year>) <volume>14</volume>:<fpage>2261</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1111/jth.13477</pub-id><pub-id pub-id-type="pmid">27546592</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sansom</surname><given-names>OJ</given-names></name><name><surname>Reed</surname><given-names>KR</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Muncan</surname><given-names>V</given-names></name><name><surname>Winton</surname><given-names>DJ</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine</article-title>. <source/>J Biol Chem. (<year>2005</year>) <volume>280</volume>:<fpage>28463</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M500191200</pub-id><pub-id pub-id-type="pmid">15946945</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gill</surname><given-names>AJ</given-names></name><name><surname>Issacs</surname><given-names>JD</given-names></name><name><surname>Atmore</surname><given-names>B</given-names></name><name><surname>Johns</surname><given-names>A</given-names></name><name><surname>Delbridge</surname><given-names>LW</given-names></name><etal></etal></person-group>. <article-title>The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer</article-title>. <source/>Hum Pathol. (<year>2012</year>) <volume>43</volume>:<fpage>1044</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.humpath.2011.08.013</pub-id><pub-id pub-id-type="pmid">22204713</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerard</surname><given-names>C</given-names></name><name><surname>Goldbeter</surname><given-names>A</given-names></name></person-group>. <article-title>Temporal self-organization of the cyclin/Cdk network driving the mammalian cell cycle</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2009</year>) <volume>106</volume>:<fpage>21643</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0903827106</pub-id><pub-id pub-id-type="pmid">20007375</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldbeter</surname><given-names>A</given-names></name></person-group>. <article-title>Computational approaches to cellular rhythms</article-title>. <source/>Nature. (<year>2002</year>) <volume>420</volume>:<fpage>238</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1038/nature01259</pub-id><pub-id pub-id-type="pmid">12432409</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olmeda</surname><given-names>D</given-names></name><name><surname>Castel</surname><given-names>S</given-names></name><name><surname>Vilaro</surname><given-names>S</given-names></name><name><surname>Cano</surname><given-names>A</given-names></name></person-group>. <article-title>Beta-catenin regulation during the cell cycle: implications in G2/M and apoptosis</article-title>. <source/>Mol Biol Cell. (<year>2003</year>) <volume>14</volume>:<fpage>2844</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.e03-01-0865</pub-id><pub-id pub-id-type="pmid">12857869</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>G</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>YL</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Karaulanov</surname><given-names>E</given-names></name><name><surname>Bartscherer</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Cell cycle control of wnt receptor activation</article-title>. <source/>Dev Cell. (<year>2009</year>) <volume>17</volume>:<fpage>788</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2009.11.006</pub-id><pub-id pub-id-type="pmid">20059949</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadjihannas</surname><given-names>MV</given-names></name><name><surname>Bernkopf</surname><given-names>DB</given-names></name><name><surname>Bruckner</surname><given-names>M</given-names></name><name><surname>Behrens</surname><given-names>J</given-names></name></person-group>. <article-title>Cell cycle control of Wnt/beta-catenin signalling by conductin/axin2 through CDC20</article-title>. <source/>EMBO Rep. (<year>2012</year>) <volume>13</volume>:<fpage>347</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1038/embor.2012.12</pub-id><pub-id pub-id-type="pmid">22322943</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prigogine</surname><given-names>I</given-names></name><name><surname>Nicolis</surname><given-names>G</given-names></name><name><surname>Babloyantz</surname><given-names>A</given-names></name></person-group>. <article-title>Nonequilibrium problems in biological phenomena</article-title>. <source/>Ann NY Acad Sci. (<year>1974</year>) <volume>231</volume>:<fpage>99</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1974.tb20557.x</pub-id><pub-id pub-id-type="pmid">4522899</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kondepudi</surname><given-names>D</given-names></name><name><surname>Prigogine</surname><given-names>I</given-names></name></person-group>
<source/>Modern Thermodynamics From Heat Engines to Dissipative Structures.
<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Wiley &amp; Sons</publisher-name> (<year>1999</year>).</mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardee</surname><given-names>AB</given-names></name></person-group>. <article-title>A restriction point for control of normal animal cell proliferation</article-title>. <source/>Proc Natl Acad Sci USA. (<year>1974</year>) <volume>71</volume>:<fpage>1286</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.71.4.1286</pub-id><pub-id pub-id-type="pmid">4524638</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourquie</surname><given-names>O</given-names></name></person-group>. <article-title>The segmentation clock: converting embryonic time into spatial pattern</article-title>. <source/>Science. (<year>2003</year>) <volume>301</volume>:<fpage>328</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1126/science.1085887</pub-id><pub-id pub-id-type="pmid">12869750</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldbeter</surname><given-names>A</given-names></name><name><surname>Pourquie</surname><given-names>O</given-names></name></person-group>. <article-title>Modeling the segmentation clock as a network of coupled oscillations in the Notch, Wnt and FGF signaling pathways</article-title>. <source/>J Theor Biol. (<year>2008</year>) <volume>252</volume>:<fpage>574</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtbi.2008.01.006</pub-id><pub-id pub-id-type="pmid">18308339</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coventry</surname><given-names>BJ</given-names></name><name><surname>Ashdown</surname><given-names>ML</given-names></name><name><surname>Quinn</surname><given-names>MA</given-names></name><name><surname>Markovic</surname><given-names>SN</given-names></name><name><surname>Yatomi-Clarke</surname><given-names>SL</given-names></name><name><surname>Robinson</surname><given-names>AP</given-names></name></person-group>. <article-title>CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?</article-title>
<source/>J Transl Med. (<year>2009</year>) <volume>7</volume>:<fpage>102</fpage>. <pub-id pub-id-type="doi">10.1186/1479-5876-7-102</pub-id><pub-id pub-id-type="pmid">19948067</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spitzer</surname><given-names>MH</given-names></name><name><surname>Carmi</surname><given-names>Y</given-names></name><name><surname>Reticker-Flynn</surname><given-names>NE</given-names></name><name><surname>Kwek</surname><given-names>SS</given-names></name><name><surname>Madhireddy</surname><given-names>D</given-names></name><name><surname>Martins</surname><given-names>MM</given-names></name><etal></etal></person-group>. <article-title>Systemic immunity is required for effective cancer immunotherapy</article-title>. <source/>Cell. (<year>2017</year>) <volume>168</volume>:<fpage>487</fpage>–<lpage>502</lpage>.e15. <pub-id pub-id-type="doi">10.1016/j.cell.2016.12.022</pub-id><pub-id pub-id-type="pmid">28111070</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>AM</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>JQ</given-names></name><name><surname>Kim</surname><given-names>TS</given-names></name><name><surname>Cohen</surname><given-names>NA</given-names></name><name><surname>Beckman</surname><given-names>MJ</given-names></name><etal></etal></person-group>. <article-title>PD-1/PD-L1 Blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors</article-title>. <source/>Clin Cancer Res. (<year>2017</year>) <volume>23</volume>:<fpage>454</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-1163</pub-id><pub-id pub-id-type="pmid">27470968</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Durham</surname><given-names>JN</given-names></name><name><surname>Smith</surname><given-names>KN</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bartlett</surname><given-names>BR</given-names></name><name><surname>Aulakh</surname><given-names>LK</given-names></name><etal></etal></person-group>. <article-title>Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade</article-title>. <source/>Science. (<year>2017</year>) <volume>357</volume>:<fpage>409</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1126/science.aan6733</pub-id><pub-id pub-id-type="pmid">28596308</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>McLellan</surname><given-names>MD</given-names></name><name><surname>Vandin</surname><given-names>F</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Niu</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Mutational landscape and significance across 12 major cancer types</article-title>. <source/>Nature. (<year>2013</year>) <volume>502</volume>:<fpage>333</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature12634</pub-id><pub-id pub-id-type="pmid">24132290</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinhart</surname><given-names>Z</given-names></name><name><surname>Pavlovic</surname><given-names>Z</given-names></name><name><surname>Chandrashekhar</surname><given-names>M</given-names></name><name><surname>Hart</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal></etal></person-group>
<article-title>Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors</article-title>. <source/>Nat Med. (<year>2017</year>) <volume>23</volume>:<fpage>60</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4219</pub-id><pub-id pub-id-type="pmid">27869803</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tammela</surname><given-names>T</given-names></name><name><surname>Sanchez-Rivera</surname><given-names>FJ</given-names></name><name><surname>Cetinbas</surname><given-names>NM</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Joshi</surname><given-names>NS</given-names></name><name><surname>Helenius</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma</article-title>. <source/>Nature. (<year>2017</year>) <volume>545</volume>:<fpage>355</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature22334</pub-id><pub-id pub-id-type="pmid">28489818</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group>. <article-title>Wnt/β-catenin signaling, disease, and emerging therapeutic modalities</article-title>. <source/>Cell. (<year>2017</year>) <volume>169</volume>:<fpage>985</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.05.016</pub-id><pub-id pub-id-type="pmid">28575679</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganesh</surname><given-names>S</given-names></name><name><surname>Shui</surname><given-names>X</given-names></name><name><surname>Craig</surname><given-names>KP</given-names></name><name><surname>Koser</surname><given-names>ML</given-names></name><name><surname>Chopda</surname><given-names>GR</given-names></name><name><surname>Cyr</surname><given-names>WA</given-names></name><etal></etal></person-group>. <article-title>β-Catenin mRNA silencing and MEK inhibition display synergistic efficacy in preclinical tumor models</article-title>. <source/>Mol Cancer Therap. (<year>2018</year>) <volume>17</volume>:<fpage>544</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0605</pub-id><pub-id pub-id-type="pmid">29282298</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganesh</surname><given-names>S</given-names></name><name><surname>Shui</surname><given-names>X</given-names></name><name><surname>Craig</surname><given-names>KP</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Brown</surname><given-names>BD</given-names></name><etal></etal></person-group>. <article-title>RNAi-mediated β-catenin inhibition promotes T cell infiltration and antitumor activity in combination with immune checkpoint blockade</article-title>. <source/>Mol Ther. (<year>2018</year>) <volume>26</volume>:<fpage>2567</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2018.09.005</pub-id><pub-id pub-id-type="pmid">30274786</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Oosterwegel</surname><given-names>M</given-names></name><name><surname>Dooijes</surname><given-names>D</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group>. <article-title>Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box</article-title>. <source/>EMBO J. (<year>1991</year>) <volume>10</volume>:<fpage>123</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1002/j.1460-2075.1991.tb07928.x</pub-id><pub-id pub-id-type="pmid">1989880</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>XS</given-names></name><name><surname>Palmer</surname><given-names>DC</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Hinrichs</surname><given-names>CS</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><etal></etal></person-group>. <article-title>Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells</article-title>. <source/>Nat Med. (<year>2009</year>) <volume>15</volume>:<fpage>808</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/nm.1982</pub-id><pub-id pub-id-type="pmid">19525962</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becht</surname><given-names>E</given-names></name><name><surname>Giraldo</surname><given-names>NA</given-names></name><name><surname>Dieu-Nosjean</surname><given-names>MC</given-names></name><name><surname>Sautes-Fridman</surname><given-names>C</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name></person-group>. <article-title>Cancer immune contexture and immunotherapy</article-title>. <source/>Curr Opin Immunol. (<year>2016</year>) <volume>39</volume>:<fpage>7</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2015.11.009</pub-id><pub-id pub-id-type="pmid">26708937</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y</given-names></name><name><surname>Schussler</surname><given-names>O</given-names></name><name><surname>Sakic</surname><given-names>A</given-names></name><name><surname>Rincon-Garriz</surname><given-names>JM</given-names></name><name><surname>Soulie</surname><given-names>P</given-names></name><name><surname>Bochaton-Piallat</surname><given-names>ML</given-names></name><etal></etal></person-group>. <article-title>Human bone marrow contains mesenchymal stromal stem cells that differentiate <italic>in vitro</italic> into contractile myofibroblasts controlling T lymphocyte proliferation</article-title>. <source/>Stem Cells Int. (<year>2018</year>) <volume>2018</volume>:<fpage>6134787</fpage>. <pub-id pub-id-type="doi">10.1155/2018/6134787</pub-id><pub-id pub-id-type="pmid">29853916</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma</article-title>. <source/>Oncotarget. (<year>2015</year>) <volume>6</volume>:<fpage>42276</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.5514</pub-id><pub-id pub-id-type="pmid">26474277</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>EW</given-names></name><name><surname>Broz</surname><given-names>ML</given-names></name><name><surname>Binnewies</surname><given-names>M</given-names></name><name><surname>Headley</surname><given-names>MB</given-names></name><name><surname>Nelson</surname><given-names>AE</given-names></name><name><surname>Wolf</surname><given-names>DM</given-names></name><etal></etal></person-group>. <article-title>Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma</article-title>. <source/>Cancer Cell. (<year>2016</year>) <volume>30</volume>:<fpage>324</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2016.06.003</pub-id><pub-id pub-id-type="pmid">27424807</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spranger</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>D</given-names></name><name><surname>Horton</surname><given-names>B</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name></person-group>. <article-title>Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy</article-title>. <source/>Cancer Cell. (<year>2017</year>) <volume>31</volume>:<fpage>711</fpage>–<lpage>23</lpage>.e4. <pub-id pub-id-type="doi">10.1016/j.ccell.2017.04.003</pub-id><pub-id pub-id-type="pmid">28486109</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>SB</given-names></name><name><surname>Smith</surname><given-names>NL</given-names></name><name><surname>McDougal</surname><given-names>C</given-names></name><name><surname>Pepper</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Yap</surname><given-names>GS</given-names></name><etal></etal></person-group>. <article-title>Beta-catenin signaling drives differentiation and proinflammatory function of IRF8-dependent dendritic cells</article-title>. <source/>J Immunol. (<year>2015</year>) <volume>194</volume>:<fpage>210</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1402453</pub-id><pub-id pub-id-type="pmid">25416805</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Kinder</surname><given-names>M</given-names></name><name><surname>Matsushita</surname><given-names>H</given-names></name><name><surname>Mashayekhi</surname><given-names>M</given-names></name><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Archambault</surname><given-names>JM</given-names></name><etal></etal></person-group>. <article-title>Type I interferon is selectively required by dendritic cells for immune rejection of tumors</article-title>. <source/>J Exp Med. (<year>2011</year>) <volume>208</volume>:<fpage>1989</fpage>–<lpage>2003</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20101158</pub-id><pub-id pub-id-type="pmid">21930769</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Hu-Lieskovan</surname><given-names>S</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name></person-group>. <article-title>Primary, adaptive, and acquired resistance to cancer immunotherapy</article-title>. <source/>Cell. (<year>2017</year>) <volume>168</volume>:<fpage>707</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.01.017</pub-id><pub-id pub-id-type="pmid">28187290</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name></person-group>. <article-title>A critical role for the regulated wnt-myc pathway in naive T cell survival</article-title>. <source/>J Immunol. (<year>2015</year>) <volume>194</volume>:<fpage>158</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1401238</pub-id><pub-id pub-id-type="pmid">25429066</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corthay</surname><given-names>A</given-names></name><name><surname>Skovseth</surname><given-names>DK</given-names></name><name><surname>Lundin</surname><given-names>KU</given-names></name><name><surname>Rosjo</surname><given-names>E</given-names></name><name><surname>Omholt</surname><given-names>H</given-names></name><name><surname>Hofgaard</surname><given-names>PO</given-names></name><etal></etal></person-group>. <article-title>Primary antitumor immune response mediated by CD4+ T cells</article-title>. <source/>Immunity. (<year>2005</year>) <volume>22</volume>:<fpage>371</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2005.02.003</pub-id><pub-id pub-id-type="pmid">15780993</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuntoli</surname><given-names>RL</given-names><suffix>II</suffix></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Kennedy</surname><given-names>R</given-names></name><name><surname>Celis</surname><given-names>E</given-names></name></person-group>. <article-title>Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function</article-title>. <source/>Clin Cancer Res. (<year>2002</year>) <volume>8</volume>:<fpage>922</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="pmid">11895927</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorcini</surname><given-names>D</given-names></name><name><surname>Bruscoli</surname><given-names>S</given-names></name><name><surname>Frammartino</surname><given-names>T</given-names></name><name><surname>Cimino</surname><given-names>M</given-names></name><name><surname>Mazzon</surname><given-names>E</given-names></name><name><surname>Galuppo</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Wnt/β-Catenin Signaling Induces Integrin α4β1 in T cells and promotes a progressive neuroinflammatory disease in mice</article-title>. <source/>J Immunol. (<year>2017</year>) <volume>199</volume>:<fpage>3031</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1700247</pub-id><pub-id pub-id-type="pmid">28939758</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Colorectal cancer cells suppress CD4+ T cells immunity through canonical Wnt signaling</article-title>. <source/>Oncotarget. (<year>2017</year>) <volume>8</volume>:<fpage>15168</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.14834</pub-id><pub-id pub-id-type="pmid">28147310</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lengfeld</surname><given-names>JE</given-names></name><name><surname>Lutz</surname><given-names>SE</given-names></name><name><surname>Smith</surname><given-names>JR</given-names></name><name><surname>Diaconu</surname><given-names>C</given-names></name><name><surname>Scott</surname><given-names>C</given-names></name><name><surname>Kofman</surname><given-names>SB</given-names></name><etal></etal></person-group>. <article-title>Endothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2017</year>) <volume>114</volume>:<fpage>E1168</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1609905114</pub-id><pub-id pub-id-type="pmid">28137846</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>A</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group>. <article-title>Regulatory T cells in cancer immunotherapy</article-title>. <source/>Cell Res. (<year>2017</year>) <volume>27</volume>:<fpage>109</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2016.151</pub-id><pub-id pub-id-type="pmid">27995907</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curiel</surname><given-names>TJ</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Mottram</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</article-title>. <source/>Nat Med. (<year>2004</year>) <volume>10</volume>:<fpage>942</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nm1093</pub-id><pub-id pub-id-type="pmid">15322536</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez</surname><given-names>I</given-names></name><name><surname>Sonenshein</surname><given-names>GE</given-names></name><name><surname>Seldin</surname><given-names>DC</given-names></name></person-group>. <article-title>Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer</article-title>. <source/>Cell Mol Life Sci. (<year>2009</year>) <volume>66</volume>:<fpage>1850</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-009-9153-z</pub-id><pub-id pub-id-type="pmid">19387549</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulges</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Reuter</surname><given-names>S</given-names></name><name><surname>Gerlitzki</surname><given-names>B</given-names></name><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Grebe</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses <italic>in vivo</italic></article-title>. <source/>Nat Immunol. (<year>2015</year>) <volume>16</volume>:<fpage>267</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3083</pub-id><pub-id pub-id-type="pmid">25599562</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Strome</surname><given-names>SE</given-names></name><name><surname>Salomao</surname><given-names>DR</given-names></name><name><surname>Tamura</surname><given-names>H</given-names></name><name><surname>Hirano</surname><given-names>F</given-names></name><name><surname>Flies</surname><given-names>DB</given-names></name><etal></etal></person-group>. <article-title>Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion</article-title>. <source/>Nat Med. (<year>2002</year>) <volume>8</volume>:<fpage>793</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1038/nm730</pub-id><pub-id pub-id-type="pmid">12091876</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blank</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>I</given-names></name><name><surname>Peterson</surname><given-names>AC</given-names></name><name><surname>Spiotto</surname><given-names>M</given-names></name><name><surname>Iwai</surname><given-names>Y</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells</article-title>. <source/>Cancer Res. (<year>2004</year>) <volume>64</volume>:<fpage>1140</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3259</pub-id><pub-id pub-id-type="pmid">14871849</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casey</surname><given-names>SC</given-names></name><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Do</surname><given-names>R</given-names></name><name><surname>Walz</surname><given-names>S</given-names></name><name><surname>Fitzgerald</surname><given-names>KN</given-names></name><etal></etal></person-group>. <article-title>MYC regulates the antitumor immune response through CD47 and PD-L1</article-title>. <source/>Science. (<year>2016</year>) <volume>352</volume>:<fpage>227</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1126/science.aac9935</pub-id><pub-id pub-id-type="pmid">26966191</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malladi</surname><given-names>S</given-names></name><name><surname>Macalinao</surname><given-names>DG</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Basnet</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Metastatic latency and immune evasion through autocrine inhibition of WNT</article-title>. <source/>Cell. (<year>2016</year>) <volume>165</volume>:<fpage>45</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.02.025</pub-id><pub-id pub-id-type="pmid">27015306</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>DR</given-names></name><name><surname>Krummel</surname><given-names>MF</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group>. <article-title>Enhancement of antitumor immunity by CTLA-4 blockade</article-title>. <source/>Science. (<year>1996</year>) <volume>271</volume>:<fpage>1734</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1126/science.271.5256.1734</pub-id><pub-id pub-id-type="pmid">8596936</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>Y</given-names></name><name><surname>Agata</surname><given-names>Y</given-names></name><name><surname>Shibahara</surname><given-names>K</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group>. <article-title>Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death</article-title>. <source/>EMBO J. (<year>1992</year>) <volume>11</volume>:<fpage>3887</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1002/j.1460-2075.1992.tb05481.x</pub-id><pub-id pub-id-type="pmid">1396582</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>ED</given-names></name><name><surname>Hurwitz</surname><given-names>AA</given-names></name><name><surname>Foster</surname><given-names>BA</given-names></name><name><surname>Madias</surname><given-names>C</given-names></name><name><surname>Feldhaus</surname><given-names>AL</given-names></name><name><surname>Greenberg</surname><given-names>NM</given-names></name><etal></etal></person-group>. <article-title>Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer</article-title>. <source/>Proc Natl Acad Sci USA. (<year>1997</year>) <volume>94</volume>:<fpage>8099</fpage>–<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.94.15.8099</pub-id><pub-id pub-id-type="pmid">9223321</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>H</given-names></name><name><surname>Nose</surname><given-names>M</given-names></name><name><surname>Hiai</surname><given-names>H</given-names></name><name><surname>Minato</surname><given-names>N</given-names></name><name><surname>Honjo</surname><given-names>T</given-names></name></person-group>. <article-title>Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor</article-title>. <source/>Immunity. (<year>1999</year>) <volume>11</volume>:<fpage>141</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-7613(00)80089-8</pub-id><pub-id pub-id-type="pmid">10485649</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabbiani</surname><given-names>G</given-names></name><name><surname>Ryan</surname><given-names>GB</given-names></name><name><surname>Majne</surname><given-names>G</given-names></name></person-group>. <article-title>Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction</article-title>. <source/>Experientia. (<year>1971</year>) <volume>27</volume>:<fpage>549</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1007/BF02147594</pub-id><pub-id pub-id-type="pmid">5132594</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orimo</surname><given-names>A</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group>. <article-title>Heterogeneity of stromal fibroblasts in tumors</article-title>. <source/>Cancer Biol Ther. (<year>2007</year>) <volume>6</volume>:<fpage>618</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4161/cbt.6.4.4255</pub-id><pub-id pub-id-type="pmid">18027438</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>H</given-names></name><name><surname>Mundel</surname><given-names>TM</given-names></name><name><surname>Kieran</surname><given-names>MW</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name></person-group>. <article-title>Identification of fibroblast heterogeneity in the tumor microenvironment</article-title>. <source/>Cancer Biol Ther. (<year>2006</year>) <volume>5</volume>:<fpage>1640</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.4161/cbt.5.12.3354</pub-id><pub-id pub-id-type="pmid">17106243</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heuberger</surname><given-names>J</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name></person-group>. <article-title>Interplay of cadherin-mediated cell adhesion and canonical wnt signaling</article-title>. <source/>Cold Spring Harb Perspect Biol. (<year>2010</year>) <volume>2</volume>:<fpage>a002915</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a002915</pub-id><pub-id pub-id-type="pmid">20182623</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomasek</surname><given-names>JJ</given-names></name><name><surname>Gabbiani</surname><given-names>G</given-names></name><name><surname>Hinz</surname><given-names>B</given-names></name><name><surname>Chaponnier</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>RA</given-names></name></person-group>. <article-title>Myofibroblasts and mechano-regulation of connective tissue remodelling</article-title>. <source/>Nat Rev Mol Cell Biol. (<year>2002</year>) <volume>3</volume>:<fpage>349</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1038/nrm809</pub-id><pub-id pub-id-type="pmid">11988769</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dvorak</surname><given-names>HF</given-names></name></person-group>
<article-title>Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing</article-title>. <source/>N Engl J Med. (<year>1986</year>) <volume>315</volume>:<fpage>1650</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198612253152606</pub-id><pub-id pub-id-type="pmid">3537791</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>M</given-names></name><name><surname>Werner</surname><given-names>S</given-names></name></person-group>. <article-title>Cancer as an overhealing wound: an old hypothesis revisited</article-title>. <source/>Nat Rev Mol Cell Biol. (<year>2008</year>) <volume>9</volume>:<fpage>628</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2455</pub-id><pub-id pub-id-type="pmid">18628784</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group>. <article-title>The extracellular matrix: not just pretty fibrils</article-title>. <source/>Science. (<year>2009</year>) <volume>326</volume>:<fpage>1216</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.1176009</pub-id><pub-id pub-id-type="pmid">19965464</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Fingleton</surname><given-names>B</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name></person-group>. <article-title>Matrix metalloproteinase inhibitors and cancer: trials and tribulations</article-title>. <source/>Science. (<year>2002</year>) <volume>295</volume>:<fpage>2387</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1126/science.1067100</pub-id><pub-id pub-id-type="pmid">11923519</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webber</surname><given-names>J</given-names></name><name><surname>Steadman</surname><given-names>R</given-names></name><name><surname>Mason</surname><given-names>MD</given-names></name><name><surname>Tabi</surname><given-names>Z</given-names></name><name><surname>Clayton</surname><given-names>A</given-names></name></person-group>. <article-title>Cancer exosomes trigger fibroblast to myofibroblast differentiation</article-title>. <source/>Cancer Res. (<year>2010</year>) <volume>70</volume>:<fpage>9621</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1722</pub-id><pub-id pub-id-type="pmid">21098712</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiery</surname><given-names>JP</given-names></name></person-group>. <article-title>Epithelial-mesenchymal transitions in tumour progression</article-title>. <source/>Nat Rev Cancer. (<year>2002</year>) <volume>2</volume>:<fpage>442</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1038/nrc822</pub-id><pub-id pub-id-type="pmid">12189386</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armulik</surname><given-names>A</given-names></name><name><surname>Genove</surname><given-names>G</given-names></name><name><surname>Betsholtz</surname><given-names>C</given-names></name></person-group>. <article-title>Pericytes: developmental, physiological, and pathological perspectives, problems, and promises</article-title>. <source/>Dev cell. (<year>2011</year>) <volume>21</volume>:<fpage>193</fpage>–<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2011.07.001</pub-id><pub-id pub-id-type="pmid">21839917</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kidd</surname><given-names>S</given-names></name><name><surname>Spaeth</surname><given-names>E</given-names></name><name><surname>Watson</surname><given-names>K</given-names></name><name><surname>Burks</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Klopp</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma</article-title>. <source/>PLoS ONE. (<year>2012</year>) <volume>7</volume>:<fpage>e30563</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0030563</pub-id><pub-id pub-id-type="pmid">22363446</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>G</given-names></name><name><surname>Sangai</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Hasebe</surname><given-names>T</given-names></name><name><surname>Endoh</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title><italic>In vivo</italic> and <italic>in vitro</italic> characterization of human fibroblasts recruited selectively into human cancer stroma</article-title>. <source/>Int J Cancer. (<year>2005</year>) <volume>117</volume>:<fpage>212</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.21199</pub-id><pub-id pub-id-type="pmid">15900602</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Direkze</surname><given-names>NC</given-names></name><name><surname>Hodivala-Dilke</surname><given-names>K</given-names></name><name><surname>Jeffery</surname><given-names>R</given-names></name><name><surname>Hunt</surname><given-names>T</given-names></name><name><surname>Poulsom</surname><given-names>R</given-names></name><name><surname>Oukrif</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts</article-title>. <source/>Cancer Res. (<year>2004</year>) <volume>64</volume>:<fpage>8492</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1708</pub-id><pub-id pub-id-type="pmid">15574751</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>B</given-names></name><name><surname>Dembinski</surname><given-names>J</given-names></name><name><surname>Sasser</surname><given-names>AK</given-names></name><name><surname>Studeny</surname><given-names>M</given-names></name><name><surname>Andreeff</surname><given-names>M</given-names></name><name><surname>Marini</surname><given-names>F</given-names></name></person-group>. <article-title>Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles</article-title>. <source/>Int J Hematol. (<year>2007</year>) <volume>86</volume>:<fpage>8</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1532/IJH97.06230</pub-id><pub-id pub-id-type="pmid">17675260</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studeny</surname><given-names>M</given-names></name><name><surname>Marini</surname><given-names>FC</given-names></name><name><surname>Dembinski</surname><given-names>JL</given-names></name><name><surname>Zompetta</surname><given-names>C</given-names></name><name><surname>Cabreira-Hansen</surname><given-names>M</given-names></name><name><surname>Bekele</surname><given-names>BN</given-names></name><etal></etal></person-group>. <article-title>Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents</article-title>. <source/>J Natl Cancer Instit. (<year>2004</year>) <volume>96</volume>:<fpage>1593</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djh299</pub-id><pub-id pub-id-type="pmid">15523088</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>SC</given-names></name><name><surname>Deng</surname><given-names>WP</given-names></name><name><surname>Yang</surname><given-names>WK</given-names></name><name><surname>Liu</surname><given-names>RS</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Su</surname><given-names>TC</given-names></name><etal></etal></person-group>. <article-title>Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in <italic>vivo</italic> positron emission tomography imaging</article-title>. <source/>Clin Cancer Res. (<year>2005</year>) <volume>11</volume>:<fpage>7749</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0876</pub-id><pub-id pub-id-type="pmid">16278396</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menon</surname><given-names>LG</given-names></name><name><surname>Picinich</surname><given-names>S</given-names></name><name><surname>Koneru</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>SY</given-names></name><name><surname>Koneru</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells</article-title>. <source/>Stem Cells. (<year>2007</year>) <volume>25</volume>:<fpage>520</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1634/stemcells.2006-0257</pub-id><pub-id pub-id-type="pmid">17053212</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>PJ</given-names></name><name><surname>Mishra</surname><given-names>PJ</given-names></name><name><surname>Humeniuk</surname><given-names>R</given-names></name><name><surname>Medina</surname><given-names>DJ</given-names></name><name><surname>Alexe</surname><given-names>G</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><etal></etal></person-group>. <article-title>Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells</article-title>. <source/>Cancer Res. (<year>2008</year>) <volume>68</volume>:<fpage>4331</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0943</pub-id><pub-id pub-id-type="pmid">18519693</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oft</surname><given-names>M</given-names></name><name><surname>Heider</surname><given-names>KH</given-names></name><name><surname>Beug</surname><given-names>H</given-names></name></person-group>. <article-title>TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis</article-title>. <source/>Curr Biol. (<year>1998</year>) <volume>8</volume>:<fpage>1243</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/S0960-9822(07)00533-7</pub-id><pub-id pub-id-type="pmid">9822576</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bierie</surname><given-names>B</given-names></name><name><surname>Moses</surname><given-names>HL</given-names></name></person-group>. <article-title>Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer</article-title>. <source/>Nat Rev Cancer. (<year>2006</year>) <volume>6</volume>:<fpage>506</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/nrc1926</pub-id><pub-id pub-id-type="pmid">16794634</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardali</surname><given-names>K</given-names></name><name><surname>Moustakas</surname><given-names>A</given-names></name></person-group>. <article-title>Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer</article-title>. <source/>Biochim Biophys acta. (<year>2007</year>) <volume>1775</volume>:<fpage>21</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbcan.2006.06.004</pub-id><pub-id pub-id-type="pmid">16904831</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikushima</surname><given-names>H</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name></person-group>. <article-title>TGFbeta signalling: a complex web in cancer progression</article-title>. <source/>Nat Rev Cancer. (<year>2010</year>) <volume>10</volume>:<fpage>415</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2853</pub-id><pub-id pub-id-type="pmid">20495575</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>GB</given-names></name><name><surname>Strickland</surname><given-names>P</given-names></name><name><surname>Coleman</surname><given-names>S</given-names></name><name><surname>Daniel</surname><given-names>CW</given-names></name></person-group>. <article-title>Epithelium-dependent extracellular matrix synthesis in transforming growth factor-beta 1-growth-inhibited mouse mammary gland</article-title>. <source/>J Cell Biol. (<year>1990</year>) <volume>110</volume>:<fpage>2209</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.110.6.2209</pub-id><pub-id pub-id-type="pmid">2351697</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweetwyne</surname><given-names>MT</given-names></name><name><surname>Murphy-Ullrich</surname><given-names>JE</given-names></name></person-group>. <article-title>Thrombospondin1 in tissue repair and fibrosis: TGF-β-dependent and independent mechanisms</article-title>. <source/>Matrix Biol. (<year>2012</year>) <volume>31</volume>:<fpage>178</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.matbio.2012.01.006</pub-id><pub-id pub-id-type="pmid">22266026</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todorovic</surname><given-names>V</given-names></name><name><surname>Rifkin</surname><given-names>DB</given-names></name></person-group>. <article-title>LTBPs, more than just an escort service</article-title>. <source/>J Cell Biochem. (<year>2012</year>) <volume>113</volume>:<fpage>410</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.23385</pub-id><pub-id pub-id-type="pmid">22223425</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azuma</surname><given-names>H</given-names></name><name><surname>Ehata</surname><given-names>S</given-names></name><name><surname>Miyazaki</surname><given-names>H</given-names></name><name><surname>Watabe</surname><given-names>T</given-names></name><name><surname>Maruyama</surname><given-names>O</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells</article-title>. <source/>J Natl Cancer Instit. (<year>2005</year>) <volume>97</volume>:<fpage>1734</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/dji399</pub-id><pub-id pub-id-type="pmid">16333029</pub-id></mixed-citation>
</ref>
<ref id="B131">
<label>131.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padua</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Nadal</surname><given-names>C</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name><name><surname>Gomis</surname><given-names>RR</given-names></name><etal></etal></person-group>. <article-title>TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4</article-title>. <source/>Cell. (<year>2008</year>) <volume>133</volume>:<fpage>66</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.01.046</pub-id><pub-id pub-id-type="pmid">18394990</pub-id></mixed-citation>
</ref>
<ref id="B132">
<label>132.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guasch</surname><given-names>G</given-names></name><name><surname>Schober</surname><given-names>M</given-names></name><name><surname>Pasolli</surname><given-names>HA</given-names></name><name><surname>Conn</surname><given-names>EB</given-names></name><name><surname>Polak</surname><given-names>L</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name></person-group>. <article-title>Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia</article-title>. <source/>Cancer Cell. (<year>2007</year>) <volume>12</volume>:<fpage>313</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2007.08.020</pub-id><pub-id pub-id-type="pmid">17936557</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>Y</given-names></name><name><surname>Acar</surname><given-names>A</given-names></name><name><surname>Eaton</surname><given-names>EN</given-names></name><name><surname>Mellody</surname><given-names>KT</given-names></name><name><surname>Scheel</surname><given-names>C</given-names></name><name><surname>Ben-Porath</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2010</year>) <volume>107</volume>:<fpage>20009</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1013805107</pub-id><pub-id pub-id-type="pmid">21041659</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annes</surname><given-names>JP</given-names></name><name><surname>Munger</surname><given-names>JS</given-names></name><name><surname>Rifkin</surname><given-names>DB</given-names></name></person-group>. <article-title>Making sense of latent TGFbeta activation</article-title>. <source/>J Cell Sci. (<year>2003</year>) <volume>116</volume>(Pt 2):<fpage>217</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.00229</pub-id><pub-id pub-id-type="pmid">12482908</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyytiainen</surname><given-names>M</given-names></name><name><surname>Penttinen</surname><given-names>C</given-names></name><name><surname>Keski-Oja</surname><given-names>J</given-names></name></person-group>. <article-title>Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation</article-title>. <source/>Crit Rev Clin Lab Sci. (<year>2004</year>) <volume>41</volume>:<fpage>233</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1080/10408360490460933</pub-id><pub-id pub-id-type="pmid">15307633</pub-id></mixed-citation>
</ref>
<ref id="B136">
<label>136.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinz</surname><given-names>B</given-names></name><name><surname>Gabbiani</surname><given-names>G</given-names></name></person-group>. <article-title>Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives</article-title>. <source/>F1000 Biol Rep. (<year>2010</year>) <volume>2</volume>:<fpage>78</fpage>. <pub-id pub-id-type="doi">10.3410/B2-78</pub-id><pub-id pub-id-type="pmid">21170369</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derynck</surname><given-names>R</given-names></name><name><surname>Jarrett</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>EY</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name></person-group>. <article-title>The murine transforming growth factor-beta precursor</article-title>. <source/>J Biol Chem. (<year>1986</year>) <volume>261</volume>:<fpage>4377</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="pmid">3007454</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worthington</surname><given-names>JJ</given-names></name><name><surname>Klementowicz</surname><given-names>JE</given-names></name><name><surname>Travis</surname><given-names>MA</given-names></name></person-group>. <article-title>TGFbeta: a sleeping giant awoken by integrins</article-title>. <source/>Trends Biochem Sci. (<year>2011</year>) <volume>36</volume>:<fpage>47</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2010.08.002</pub-id><pub-id pub-id-type="pmid">20870411</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Mi</surname><given-names>L</given-names></name><name><surname>Walz</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Latent TGF-β structure and activation</article-title>. <source/>Nature. (<year>2011</year>) <volume>474</volume>:<fpage>343</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nature10152</pub-id><pub-id pub-id-type="pmid">21677751</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wipff</surname><given-names>PJ</given-names></name><name><surname>Hinz</surname><given-names>B</given-names></name></person-group>. <article-title>Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship</article-title>. <source/>Eur J Cell Biol. (<year>2008</year>) <volume>87</volume>:<fpage>601</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejcb.2008.01.012</pub-id><pub-id pub-id-type="pmid">18342983</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>SL</given-names></name></person-group>. <article-title>Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders</article-title>. <source/>Am J Pathol. (<year>2009</year>) <volume>175</volume>:<fpage>1362</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2009.090393</pub-id><pub-id pub-id-type="pmid">19729474</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheppard</surname><given-names>D</given-names></name></person-group>. <article-title>Integrin-mediated activation of latent transforming growth factor beta</article-title>. <source/>Cancer Metastasis Rev. (<year>2005</year>) <volume>24</volume>:<fpage>395</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-005-5131-6</pub-id><pub-id pub-id-type="pmid">16258727</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paszek</surname><given-names>MJ</given-names></name><name><surname>Zahir</surname><given-names>N</given-names></name><name><surname>Johnson</surname><given-names>KR</given-names></name><name><surname>Lakins</surname><given-names>JN</given-names></name><name><surname>Rozenberg</surname><given-names>GI</given-names></name><name><surname>Gefen</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Tensional homeostasis and the malignant phenotype</article-title>. <source/>Cancer Cell. (<year>2005</year>) <volume>8</volume>:<fpage>241</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2005.08.010</pub-id><pub-id pub-id-type="pmid">16169468</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Weaver</surname><given-names>VM</given-names></name></person-group>. <article-title>Mechanics, malignancy, and metastasis: the force journey of a tumor cell</article-title>. <source/>Cancer Metastasis Rev. (<year>2009</year>) <volume>28</volume>:<fpage>113</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-008-9173-4</pub-id><pub-id pub-id-type="pmid">19153673</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beacham</surname><given-names>DA</given-names></name><name><surname>Cukierman</surname><given-names>E</given-names></name></person-group>. <article-title>Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression</article-title>. <source/>Semin Cancer Biol. (<year>2005</year>) <volume>15</volume>:<fpage>329</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2005.05.003</pub-id><pub-id pub-id-type="pmid">15970443</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>ES</given-names></name><name><surname>Christensen</surname><given-names>PB</given-names></name><name><surname>Weis</surname><given-names>N</given-names></name></person-group>. <article-title>Transient elastography for liver fibrosis diagnosis</article-title>. <source/>Eur J Intern Med. (<year>2009</year>) <volume>20</volume>:<fpage>339</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejim.2008.09.020</pub-id><pub-id pub-id-type="pmid">19524169</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DuFort</surname><given-names>CC</given-names></name><name><surname>Paszek</surname><given-names>MJ</given-names></name><name><surname>Weaver</surname><given-names>VM</given-names></name></person-group>. <article-title>Balancing forces: architectural control of mechanotransduction</article-title>. <source/>Nat Rev Mol Cell Biol. (<year>2011</year>) <volume>12</volume>:<fpage>308</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3112</pub-id><pub-id pub-id-type="pmid">21508987</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cirri</surname><given-names>P</given-names></name><name><surname>Chiarugi</surname><given-names>P</given-names></name></person-group>. <article-title>Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression</article-title>. <source/>Cancer Metastasis Rev. (<year>2012</year>) <volume>31</volume>:<fpage>195</fpage>–<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-011-9340-x</pub-id><pub-id pub-id-type="pmid">22101652</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasanen</surname><given-names>K</given-names></name><name><surname>Vaheri</surname><given-names>A</given-names></name></person-group>. <article-title>Activation of fibroblasts in cancer stroma</article-title>. <source/>Exp Cell Res. (<year>2010</year>) <volume>316</volume>:<fpage>2713</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2010.04.032</pub-id><pub-id pub-id-type="pmid">20451516</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname><given-names>JA</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name></person-group>. <article-title>Microenvironmental regulation of metastasis</article-title>. <source/>Nat Rev Cancer. (<year>2009</year>) <volume>9</volume>:<fpage>239</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2618</pub-id><pub-id pub-id-type="pmid">19279573</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bienz</surname><given-names>M</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group>. <article-title>Linking colorectal cancer to Wnt signaling</article-title>. <source/>Cell. (<year>2000</year>) <volume>103</volume>:<fpage>311</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(00)00122-7</pub-id><pub-id pub-id-type="pmid">11057903</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group>. <article-title>Wnt meets Warburg: another piece in the puzzle?</article-title>
<source/>EMBO J. (<year>2014</year>) <volume>33</volume>:<fpage>1420</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.15252/embj.201488785</pub-id><pub-id pub-id-type="pmid">24843042</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roche</surname><given-names>TE</given-names></name><name><surname>Baker</surname><given-names>JC</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Hiromasa</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms</article-title>. <source/>Progr Nucleic Acid Res Mol Biol. (<year>2001</year>) <volume>70</volume>:<fpage>33</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/S0079-6603(01)70013-X</pub-id><pub-id pub-id-type="pmid">11642366</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brabletz</surname><given-names>T</given-names></name><name><surname>Hlubek</surname><given-names>F</given-names></name><name><surname>Spaderna</surname><given-names>S</given-names></name><name><surname>Schmalhofer</surname><given-names>O</given-names></name><name><surname>Hiendlmeyer</surname><given-names>E</given-names></name><name><surname>Jung</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin</article-title>. <source/>Cells Tissues Organs. (<year>2005</year>) <volume>179</volume>:<fpage>56</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1159/000084509</pub-id><pub-id pub-id-type="pmid">15942193</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>155.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brabletz</surname><given-names>T</given-names></name><name><surname>Jung</surname><given-names>A</given-names></name><name><surname>Spaderna</surname><given-names>S</given-names></name><name><surname>Hlubek</surname><given-names>F</given-names></name><name><surname>Kirchner</surname><given-names>T</given-names></name></person-group>. <article-title>Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression</article-title>. <source/>Nat Rev Cancer. (<year>2005</year>) <volume>5</volume>:<fpage>744</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nrc1694</pub-id><pub-id pub-id-type="pmid">16148886</pub-id></mixed-citation>
</ref>
<ref id="B156">
<label>156.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaus</surname><given-names>A</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name></person-group>. <article-title>Wnt signalling and its impact on development and cancer</article-title>. <source/>Nat Rev Cancer. (<year>2008</year>) <volume>8</volume>:<fpage>387</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2389</pub-id><pub-id pub-id-type="pmid">18432252</pub-id></mixed-citation>
</ref>
<ref id="B157">
<label>157.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koukourakis</surname><given-names>MI</given-names></name><name><surname>Giatromanolaki</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Sivridis</surname><given-names>E</given-names></name></person-group>. <article-title>Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma</article-title>. <source/>Cancer Res. (<year>2006</year>) <volume>66</volume>:<fpage>632</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3260</pub-id><pub-id pub-id-type="pmid">16423989</pub-id></mixed-citation>
</ref>
<ref id="B158">
<label>158.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wigfield</surname><given-names>SM</given-names></name><name><surname>Winter</surname><given-names>SC</given-names></name><name><surname>Giatromanolaki</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Koukourakis</surname><given-names>ML</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group>. <article-title>PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer</article-title>. <source/>Br J Cancer. (<year>2008</year>) <volume>98</volume>:<fpage>1975</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6604356</pub-id><pub-id pub-id-type="pmid">18542064</pub-id></mixed-citation>
</ref>
<ref id="B159">
<label>159.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumunk</surname><given-names>D</given-names></name><name><surname>Reichelt</surname><given-names>U</given-names></name><name><surname>Hildebrandt</surname><given-names>J</given-names></name><name><surname>Krause</surname><given-names>H</given-names></name><name><surname>Ebbing</surname><given-names>J</given-names></name><name><surname>Cash</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC)</article-title>. <source/>World J Urol. (<year>2013</year>) <volume>31</volume>:<fpage>1191</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s00345-012-0874-5</pub-id><pub-id pub-id-type="pmid">22544372</pub-id></mixed-citation>
</ref>
<ref id="B160">
<label>160.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>TK</given-names></name><name><surname>Aslam</surname><given-names>RS</given-names></name><name><surname>Beckert</surname><given-names>S</given-names></name><name><surname>Wagner</surname><given-names>S</given-names></name><name><surname>Ghani</surname><given-names>QP</given-names></name><name><surname>Hussain</surname><given-names>MZ</given-names></name><etal></etal></person-group>. <article-title>Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms</article-title>. <source/>Antioxid Redox Signal. (<year>2007</year>) <volume>9</volume>:<fpage>1115</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2007.1674</pub-id><pub-id pub-id-type="pmid">17567242</pub-id></mixed-citation>
</ref>
<ref id="B161">
<label>161.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name><name><surname>Lum</surname><given-names>JJ</given-names></name><name><surname>Hatzivassiliou</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group>. <article-title>The biology of cancer: metabolic reprogramming fuels cell growth and proliferation</article-title>. <source/>Cell Metab. (<year>2008</year>) <volume>7</volume>:<fpage>11</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2007.10.002</pub-id><pub-id pub-id-type="pmid">18177721</pub-id></mixed-citation>
</ref>
<ref id="B162">
<label>162.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group>. <article-title>Understanding the Warburg effect: the metabolic requirements of cell proliferation</article-title>. <source/>Science. (<year>2009</year>) <volume>324</volume>:<fpage>1029</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1126/science.1160809</pub-id><pub-id pub-id-type="pmid">19460998</pub-id></mixed-citation>
</ref>
<ref id="B163">
<label>163.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFate</surname><given-names>T</given-names></name><name><surname>Mohyeldin</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Thakar</surname><given-names>J</given-names></name><name><surname>Henriques</surname><given-names>J</given-names></name><name><surname>Halim</surname><given-names>ND</given-names></name><etal></etal></person-group>. <article-title>Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells</article-title>. <source/>J Biol Chem. (<year>2008</year>) <volume>283</volume>:<fpage>22700</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M801765200</pub-id><pub-id pub-id-type="pmid">18541534</pub-id></mixed-citation>
</ref>
<ref id="B164">
<label>164.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutendra</surname><given-names>G</given-names></name><name><surname>Dromparis</surname><given-names>P</given-names></name><name><surname>Kinnaird</surname><given-names>A</given-names></name><name><surname>Stenson</surname><given-names>TH</given-names></name><name><surname>Haromy</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>JM</given-names></name><etal></etal></person-group>. <article-title>Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer</article-title>. <source/>Oncogene. (<year>2013</year>) <volume>32</volume>:<fpage>1638</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2012.198</pub-id><pub-id pub-id-type="pmid">22614004</pub-id></mixed-citation>
</ref>
<ref id="B165">
<label>165.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>DR</given-names></name><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name><name><surname>Mancuso</surname><given-names>A</given-names></name><name><surname>Sayed</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Pfeiffer</surname><given-names>HK</given-names></name><etal></etal></person-group>. <article-title>Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2008</year>) <volume>105</volume>:<fpage>18782</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0810199105</pub-id><pub-id pub-id-type="pmid">19033189</pub-id></mixed-citation>
</ref>
<ref id="B166">
<label>166.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>CV</given-names></name></person-group>. <article-title>Rethinking the Warburg effect with Myc micromanaging glutamine metabolism</article-title>. <source/>Cancer Res. (<year>2010</year>) <volume>70</volume>:<fpage>859</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3556</pub-id><pub-id pub-id-type="pmid">20086171</pub-id></mixed-citation>
</ref>
<ref id="B167">
<label>167.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Dang</surname><given-names>CV</given-names></name></person-group>. <article-title>Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1</article-title>. <source/>Mol Cell Biol. (<year>2007</year>) <volume>27</volume>:<fpage>7381</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.00440-07</pub-id><pub-id pub-id-type="pmid">17785433</pub-id></mixed-citation>
</ref>
<ref id="B168">
<label>168.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Forbes</surname><given-names>RA</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name></person-group>. <article-title>Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis</article-title>. <source/>J Biol Chem. (<year>2002</year>) <volume>277</volume>:<fpage>23111</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M202487200</pub-id><pub-id pub-id-type="pmid">11943784</pub-id></mixed-citation>
</ref>
<ref id="B169">
<label>169.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>K</given-names></name><name><surname>Logsdon</surname><given-names>NJ</given-names></name><name><surname>Ravi</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>N</given-names></name><name><surname>Persons</surname><given-names>BP</given-names></name><name><surname>Rangarajan</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Metabolic reprogramming is required for myofibroblast contractility and differentiation</article-title>. <source/>J Biol Chem. (<year>2015</year>) <volume>290</volume>:<fpage>25427</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M115.646984</pub-id><pub-id pub-id-type="pmid">26318453</pub-id></mixed-citation>
</ref>
<ref id="B170">
<label>170.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chocarro-Calvo</surname><given-names>A</given-names></name><name><surname>Garcia-Martinez</surname><given-names>JM</given-names></name><name><surname>Ardila-Gonzalez</surname><given-names>S</given-names></name><name><surname>De la Vieja</surname><given-names>A</given-names></name><name><surname>Garcia-Jimenez</surname><given-names>C</given-names></name></person-group>. <article-title>Glucose-induced β-catenin acetylation enhances Wnt signaling in cancer</article-title>. <source/>Mol Cell. (<year>2013</year>) <volume>49</volume>:<fpage>474</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2012.11.022</pub-id><pub-id pub-id-type="pmid">23273980</pub-id></mixed-citation>
</ref>
<ref id="B171">
<label>171.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GL</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name><name><surname>Rue</surname><given-names>EA</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group>. <article-title>Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension</article-title>. <source/>Proc Natl Acad Sci USA. (<year>1995</year>) <volume>92</volume>:<fpage>5510</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.92.12.5510</pub-id><pub-id pub-id-type="pmid">7539918</pub-id></mixed-citation>
</ref>
<ref id="B172">
<label>172.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constant</surname><given-names>JS</given-names></name><name><surname>Feng</surname><given-names>JJ</given-names></name><name><surname>Zabel</surname><given-names>DD</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Suh</surname><given-names>DY</given-names></name><name><surname>Scheuenstuhl</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Lactate elicits vascular endothelial growth factor from macrophages: a possible alternative to hypoxia</article-title>. <source/>Wound Repair Regener. (<year>2000</year>) <volume>8</volume>:<fpage>353</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1111/j.1524-475X.2000.00353.x</pub-id><pub-id pub-id-type="pmid">11115148</pub-id></mixed-citation>
</ref>
<ref id="B173">
<label>173.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallee</surname><given-names>A</given-names></name><name><surname>Guillevin</surname><given-names>R</given-names></name><name><surname>Vallee</surname><given-names>JN</given-names></name></person-group>. <article-title>Vasculogenesis and angiogenesis initiation under normoxic conditions through Wnt/β-catenin pathway in gliomas</article-title>. <source/>Rev Neurosci. (<year>2018</year>) <volume>29</volume>:<fpage>71</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1515/revneuro-2017-0032</pub-id><pub-id pub-id-type="pmid">28822229</pub-id></mixed-citation>
</ref>
<ref id="B174">
<label>174.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaakkola</surname><given-names>P</given-names></name><name><surname>Mole</surname><given-names>DR</given-names></name><name><surname>Tian</surname><given-names>YM</given-names></name><name><surname>Wilson</surname><given-names>MI</given-names></name><name><surname>Gielbert</surname><given-names>J</given-names></name><name><surname>Gaskell</surname><given-names>SJ</given-names></name><etal></etal></person-group>. <article-title>Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation</article-title>. <source/>Science. (<year>2001</year>) <volume>292</volume>:<fpage>468</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1126/science.1059796</pub-id><pub-id pub-id-type="pmid">11292861</pub-id></mixed-citation>
</ref>
<ref id="B175">
<label>175.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vegran</surname><given-names>F</given-names></name><name><surname>Boidot</surname><given-names>R</given-names></name><name><surname>Michiels</surname><given-names>C</given-names></name><name><surname>Sonveaux</surname><given-names>P</given-names></name><name><surname>Feron</surname><given-names>O</given-names></name></person-group>. <article-title>Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis</article-title>. <source/>Cancer Res. (<year>2011</year>) <volume>71</volume>:<fpage>2550</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2828</pub-id><pub-id pub-id-type="pmid">21300765</pub-id></mixed-citation>
</ref>
<ref id="B176">
<label>176.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robey</surname><given-names>RB</given-names></name><name><surname>Hay</surname><given-names>N</given-names></name></person-group>
<article-title>Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis</article-title>. <source/>Semin Cancer Biol. (<year>2009</year>) <volume>19</volume>:<fpage>25</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2008.11.010</pub-id><pub-id pub-id-type="pmid">19130886</pub-id></mixed-citation>
</ref>
<ref id="B177">
<label>177.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karar</surname><given-names>J</given-names></name><name><surname>Maity</surname><given-names>A</given-names></name></person-group>. <article-title>PI3K/AKT/mTOR pathway in angiogenesis</article-title>. <source/>Front Mol Neurosci. (<year>2011</year>) <volume>4</volume>:<fpage>51</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2011.00051</pub-id><pub-id pub-id-type="pmid">22144946</pub-id></mixed-citation>
</ref>
<ref id="B178">
<label>178.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldbeter</surname><given-names>A</given-names></name><name><surname>Lefever</surname><given-names>R</given-names></name></person-group>. <article-title>Dissipative structures for an allosteric model. Application to glycolytic oscillations</article-title>. <source/>Biophys J. (<year>1972</year>) <volume>12</volume>:<fpage>1302</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-3495(72)86164-2</pub-id><pub-id pub-id-type="pmid">4263005</pub-id></mixed-citation>
</ref>
<ref id="B179">
<label>179.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prigogine</surname><given-names>I</given-names></name><name><surname>Nicolis</surname><given-names>G</given-names></name></person-group>. <article-title>Biological order, structure and instabilities</article-title>. <source/>Q Rev Biophys. (<year>1971</year>) <volume>4</volume>:<fpage>107</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1017/S0033583500000615</pub-id><pub-id pub-id-type="pmid">4257403</pub-id></mixed-citation>
</ref>
<ref id="B180">
<label>180.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y</given-names></name><name><surname>Claes</surname><given-names>V</given-names></name><name><surname>Hebert</surname><given-names>JL</given-names></name></person-group>. <article-title>PPARs, Cardiovascular metabolism, and function: near- or far-from-equilibrium pathways</article-title>. <source/>PPAR Res. (<year>2010</year>) <volume>2010</volume>:<fpage>783273</fpage>. <pub-id pub-id-type="doi">10.1155/2010/783273</pub-id><pub-id pub-id-type="pmid">20706650</pub-id></mixed-citation>
</ref>
<ref id="B181">
<label>181.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>KM</given-names></name><name><surname>Anderson</surname><given-names>NG</given-names></name></person-group>. <article-title>The protein kinase B/Akt signalling pathway in human malignancy</article-title>. <source/>Cell Signal. (<year>2002</year>) <volume>14</volume>:<fpage>381</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/S0898-6568(01)00271-6</pub-id><pub-id pub-id-type="pmid">11882383</pub-id></mixed-citation>
</ref>
<ref id="B182">
<label>182.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>BD</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group>. <article-title>AKT/PKB signaling: navigating downstream</article-title>. <source/>Cell. (<year>2007</year>) <volume>129</volume>:<fpage>1261</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2007.06.009</pub-id><pub-id pub-id-type="pmid">17604717</pub-id></mixed-citation>
</ref>
<ref id="B183">
<label>183.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgescu</surname><given-names>MM</given-names></name></person-group>. <article-title>PTEN tumor suppressor network in PI3K-Akt pathway control</article-title>. <source/>Genes Cancer. (<year>2010</year>) <volume>1</volume>:<fpage>1170</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1177/1947601911407325</pub-id><pub-id pub-id-type="pmid">21779440</pub-id></mixed-citation>
</ref>
<ref id="B184">
<label>184.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Outschoorn</surname><given-names>UE</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>Tumor microenvironment: introduction</article-title>. <source/>Semin Oncol. (<year>2014</year>) <volume>41</volume>:<fpage>145</fpage>. <pub-id pub-id-type="doi">10.1053/j.seminoncol.2014.03.007</pub-id><pub-id pub-id-type="pmid">24787288</pub-id></mixed-citation>
</ref>
<ref id="B185">
<label>185.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>R</given-names></name><name><surname>Strowig</surname><given-names>T</given-names></name><name><surname>Verma</surname><given-names>R</given-names></name><name><surname>Koduru</surname><given-names>S</given-names></name><name><surname>Hafemann</surname><given-names>A</given-names></name><name><surname>Hopf</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice</article-title>. <source/>Nat Med. (<year>2016</year>) <volume>22</volume>:<fpage>1351</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4202</pub-id><pub-id pub-id-type="pmid">27723723</pub-id></mixed-citation>
</ref>
<ref id="B186">
<label>186.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Niu</surname><given-names>W</given-names></name><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>The reverse Warburg effect is likely to be an Achilles' heel of cancer that can be exploited for cancer therapy</article-title>. <source/>Oncotarget. (<year>2017</year>) <volume>8</volume>:<fpage>57813</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.18175</pub-id><pub-id pub-id-type="pmid">28915713</pub-id></mixed-citation>
</ref>
<ref id="B187">
<label>187.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Outschoorn</surname><given-names>UE</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name></person-group>. <article-title>Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth</article-title>. <source/>Semin Cancer Biol. (<year>2014</year>) <volume>25</volume>:<fpage>47</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2014.01.005</pub-id><pub-id pub-id-type="pmid">24486645</pub-id></mixed-citation>
</ref>
<ref id="B188">
<label>188.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zu</surname><given-names>XL</given-names></name><name><surname>Guppy</surname><given-names>M</given-names></name></person-group>. <article-title>Cancer metabolism: facts, fantasy, and fiction</article-title>. <source/>Biochem Biophys Res Commun. (<year>2004</year>) <volume>313</volume>:<fpage>459</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2003.11.136</pub-id><pub-id pub-id-type="pmid">14697210</pub-id></mixed-citation>
</ref>
<ref id="B189">
<label>189.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ge</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Fang</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>MiR-34b-3 and miR-449a inhibit malignant progression of nasopharyngeal carcinoma by targeting lactate dehydrogenase A</article-title>. <source/>Oncotarget. (<year>2016</year>) <volume>7</volume>:<fpage>54838</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.10761</pub-id><pub-id pub-id-type="pmid">27458165</pub-id></mixed-citation>
</ref>
<ref id="B190">
<label>190.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Resendiz</surname><given-names>I</given-names></name><name><surname>Roman-Rosales</surname><given-names>A</given-names></name><name><surname>Garcia-Villa</surname><given-names>E</given-names></name><name><surname>Lopez-Macay</surname><given-names>A</given-names></name><name><surname>Pineda</surname><given-names>E</given-names></name><name><surname>Saavedra</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Dual regulation of energy metabolism by p53 in human cervix and breast cancer cells</article-title>. <source/>Biochim Biophys Acta. (<year>2015</year>) <volume>1853</volume>:<fpage>3266</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2015.09.033</pub-id><pub-id pub-id-type="pmid">26434996</pub-id></mixed-citation>
</ref>
<ref id="B191">
<label>191.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Enriquez</surname><given-names>S</given-names></name><name><surname>Gallardo-Perez</surname><given-names>JC</given-names></name><name><surname>Marin-Hernandez</surname><given-names>A</given-names></name><name><surname>Aguilar-Ponce</surname><given-names>JL</given-names></name><name><surname>Mandujano-Tinoco</surname><given-names>EA</given-names></name><name><surname>Meneses</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Oxidative phosphorylation as a target to arrest malignant neoplasias</article-title>. <source/>Curr Med Chem. (<year>2011</year>) <volume>18</volume>:<fpage>3156</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.2174/092986711796391561</pub-id><pub-id pub-id-type="pmid">21671858</pub-id></mixed-citation>
</ref>
<ref id="B192">
<label>192.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name></person-group>. <article-title>Regulation of the pentose phosphate pathway in cancer</article-title>. <source/>Protein Cell. (<year>2014</year>) <volume>5</volume>:<fpage>592</fpage>–<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1007/s13238-014-0082-8</pub-id><pub-id pub-id-type="pmid">25015087</pub-id></mixed-citation>
</ref>
<ref id="B193">
<label>193.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamarajugadda</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Nayak</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Manganese superoxide dismutase promotes anoikis resistance and tumor metastasis</article-title>. <source/>Cell Death Dis. (<year>2013</year>) <volume>4</volume>:<fpage>e504</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2013.20</pub-id><pub-id pub-id-type="pmid">23429290</pub-id></mixed-citation>
</ref>
<ref id="B194">
<label>194.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandujano-Tinoco</surname><given-names>EA</given-names></name><name><surname>Gallardo-Perez</surname><given-names>JC</given-names></name><name><surname>Marin-Hernandez</surname><given-names>A</given-names></name><name><surname>Moreno-Sanchez</surname><given-names>R</given-names></name><name><surname>Rodriguez-Enriquez</surname><given-names>S</given-names></name></person-group>. <article-title>Anti-mitochondrial therapy in human breast cancer multi-cellular spheroids</article-title>. <source/>Biochim Biophys Acta. (<year>2013</year>) <volume>1833</volume>:<fpage>541</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2012.11.013</pub-id><pub-id pub-id-type="pmid">23195224</pub-id></mixed-citation>
</ref>
<ref id="B195">
<label>195.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Yoon</surname><given-names>JH</given-names></name></person-group>. <article-title>Metabolic interplay between glycolysis and mitochondrial oxidation: the reverse Warburg effect and its therapeutic implication</article-title>. <source/>World J Biol Chem. (<year>2015</year>) <volume>6</volume>:<fpage>148</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.4331/wjbc.v6.i3.148</pub-id><pub-id pub-id-type="pmid">26322173</pub-id></mixed-citation>
</ref>
<ref id="B196">
<label>196.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatenby</surname><given-names>RA</given-names></name><name><surname>Smallbone</surname><given-names>K</given-names></name><name><surname>Maini</surname><given-names>PK</given-names></name><name><surname>Rose</surname><given-names>F</given-names></name><name><surname>Averill</surname><given-names>J</given-names></name><name><surname>Nagle</surname><given-names>RB</given-names></name><etal></etal></person-group>. <article-title>Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer</article-title>. <source/>Br J Cancer. (<year>2007</year>) <volume>97</volume>:<fpage>646</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6603922</pub-id><pub-id pub-id-type="pmid">17687336</pub-id></mixed-citation>
</ref>
<ref id="B197">
<label>197.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ertel</surname><given-names>A</given-names></name><name><surname>Tsirigos</surname><given-names>A</given-names></name><name><surname>Whitaker-Menezes</surname><given-names>D</given-names></name><name><surname>Birbe</surname><given-names>RC</given-names></name><name><surname>Pavlides</surname><given-names>S</given-names></name><name><surname>Martinez-Outschoorn</surname><given-names>UE</given-names></name><etal></etal></person-group>. <article-title>Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism</article-title>. <source/>Cell Cycle. (<year>2012</year>) <volume>11</volume>:<fpage>253</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.4161/cc.11.2.19006</pub-id><pub-id pub-id-type="pmid">22234241</pub-id></mixed-citation>
</ref>
<ref id="B198">
<label>198.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migneco</surname><given-names>G</given-names></name><name><surname>Whitaker-Menezes</surname><given-names>D</given-names></name><name><surname>Chiavarina</surname><given-names>B</given-names></name><name><surname>Castello-Cros</surname><given-names>R</given-names></name><name><surname>Pavlides</surname><given-names>S</given-names></name><name><surname>Pestell</surname><given-names>RG</given-names></name><etal></etal></person-group>. <article-title>Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling</article-title>. <source/>Cell Cycle. (<year>2010</year>) <volume>9</volume>:<fpage>2412</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.4161/cc.9.12.11989</pub-id><pub-id pub-id-type="pmid">20562527</pub-id></mixed-citation>
</ref>
<ref id="B199">
<label>199.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Outschoorn</surname><given-names>UE</given-names></name><name><surname>Pavlides</surname><given-names>S</given-names></name><name><surname>Whitaker-Menezes</surname><given-names>D</given-names></name><name><surname>Daumer</surname><given-names>KM</given-names></name><name><surname>Milliman</surname><given-names>JN</given-names></name><name><surname>Chiavarina</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors</article-title>. <source/>Cell Cycle. (<year>2010</year>) <volume>9</volume>:<fpage>2423</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.4161/cc.9.12.12048</pub-id><pub-id pub-id-type="pmid">20562526</pub-id></mixed-citation>
</ref>
<ref id="B200">
<label>200.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonuccelli</surname><given-names>G</given-names></name><name><surname>Whitaker-Menezes</surname><given-names>D</given-names></name><name><surname>Castello-Cros</surname><given-names>R</given-names></name><name><surname>Pavlides</surname><given-names>S</given-names></name><name><surname>Pestell</surname><given-names>RG</given-names></name><name><surname>Fatatis</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts</article-title>. <source/>Cell Cycle. (<year>2010</year>) <volume>9</volume>:<fpage>1960</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.4161/cc.9.10.11601</pub-id><pub-id pub-id-type="pmid">20495363</pub-id></mixed-citation>
</ref>
<ref id="B201">
<label>201.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Outschoorn</surname><given-names>UE</given-names></name><name><surname>Curry</surname><given-names>JM</given-names></name><name><surname>Ko</surname><given-names>YH</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Tuluc</surname><given-names>M</given-names></name><name><surname>Cognetti</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4</article-title>. <source/>Cell Cycle. (<year>2013</year>) <volume>12</volume>:<fpage>2580</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.4161/cc.25510</pub-id><pub-id pub-id-type="pmid">23860378</pub-id></mixed-citation>
</ref>
<ref id="B202">
<label>202.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Martinez-Outschoorn</surname><given-names>UE</given-names></name><name><surname>Lisanti</surname><given-names>MP</given-names></name></person-group>. <article-title>The reverse Warburg effect in osteosarcoma</article-title>. <source/>Oncotarget. (<year>2014</year>) <volume>5</volume>:<fpage>7982</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.2352</pub-id><pub-id pub-id-type="pmid">25478627</pub-id></mixed-citation>
</ref>
<ref id="B203">
<label>203.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>BC</given-names></name></person-group>. <article-title>Oscillatory behavior in enzymatic control processes</article-title>. <source/>Adv Enzyme Regul. (<year>1965</year>) <volume>3</volume>:<fpage>425</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/0065-2571(65)90067-1</pub-id><pub-id pub-id-type="pmid">5861813</pub-id></mixed-citation>
</ref>
<ref id="B204">
<label>204.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardin</surname><given-names>PE</given-names></name><name><surname>Hall</surname><given-names>JC</given-names></name><name><surname>Rosbash</surname><given-names>M</given-names></name></person-group>. <article-title>Feedback of the Drosophila period gene product on circadian cycling of its messenger RNA levels</article-title>. <source/>Nature. (<year>1990</year>) <volume>343</volume>:<fpage>536</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/343536a0</pub-id><pub-id pub-id-type="pmid">2105471</pub-id></mixed-citation>
</ref>
<ref id="B205">
<label>205.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gekakis</surname><given-names>N</given-names></name><name><surname>Staknis</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>HB</given-names></name><name><surname>Davis</surname><given-names>FC</given-names></name><name><surname>Wilsbacher</surname><given-names>LD</given-names></name><name><surname>King</surname><given-names>DP</given-names></name><etal></etal></person-group>. <article-title>Role of the CLOCK protein in the mammalian circadian mechanism</article-title>. <source/>Science. (<year>1998</year>) <volume>280</volume>:<fpage>1564</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.280.5369.1564</pub-id><pub-id pub-id-type="pmid">9616112</pub-id></mixed-citation>
</ref>
<ref id="B206">
<label>206.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogenesch</surname><given-names>JB</given-names></name><name><surname>Gu</surname><given-names>YZ</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Bradfield</surname><given-names>CA</given-names></name></person-group>. <article-title>The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors</article-title>. <source/>Proc Natl Acad Sci USA. (<year>1998</year>) <volume>95</volume>:<fpage>5474</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.95.10.5474</pub-id><pub-id pub-id-type="pmid">9576906</pub-id></mixed-citation>
</ref>
<ref id="B207">
<label>207.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahar</surname><given-names>S</given-names></name><name><surname>Zocchi</surname><given-names>L</given-names></name><name><surname>Kinoshita</surname><given-names>C</given-names></name><name><surname>Borrelli</surname><given-names>E</given-names></name><name><surname>Sassone-Corsi</surname><given-names>P</given-names></name></person-group>. <article-title>Regulation of BMAL1 protein stability and circadian function by GSK3beta-mediated phosphorylation</article-title>. <source/>PLoS ONE. (<year>2010</year>) <volume>5</volume>:<fpage>e8561</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0008561</pub-id><pub-id pub-id-type="pmid">20049328</pub-id></mixed-citation>
</ref>
<ref id="B208">
<label>208.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paschos</surname><given-names>GK</given-names></name><name><surname>Ibrahim</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>WL</given-names></name><name><surname>Kunieda</surname><given-names>T</given-names></name><name><surname>Grant</surname><given-names>G</given-names></name><name><surname>Reyes</surname><given-names>TM</given-names></name><etal></etal></person-group>. <article-title>Obesity in mice with adipocyte-specific deletion of clock component Arntl</article-title>. <source/>Nat Med. (<year>2012</year>) <volume>18</volume>:<fpage>1768</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2979</pub-id><pub-id pub-id-type="pmid">23142819</pub-id></mixed-citation>
</ref>
<ref id="B209">
<label>209.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wood</surname><given-names>PA</given-names></name><name><surname>Ansell</surname><given-names>CM</given-names></name><name><surname>Ohmori</surname><given-names>M</given-names></name><name><surname>Oh</surname><given-names>EY</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice</article-title>. <source/>J Biochem. (<year>2009</year>) <volume>145</volume>:<fpage>289</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1093/jb/mvn167</pub-id><pub-id pub-id-type="pmid">19106159</pub-id></mixed-citation>
</ref>
<ref id="B210">
<label>210.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>SL</given-names></name><name><surname>Bosnoyan-Collins</surname><given-names>L</given-names></name><name><surname>Pinnaduwage</surname><given-names>D</given-names></name><name><surname>Andrulis</surname><given-names>IL</given-names></name></person-group>. <article-title>Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors</article-title>. <source/>Neoplasia. (<year>2007</year>) <volume>9</volume>:<fpage>797</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1593/neo.07595</pub-id><pub-id pub-id-type="pmid">17971899</pub-id></mixed-citation>
</ref>
<ref id="B211">
<label>211.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Gery</surname><given-names>S</given-names></name><name><surname>Dashti</surname><given-names>A</given-names></name><name><surname>Yin</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>A role for the clock gene per1 in prostate cancer</article-title>. <source/>Cancer Res. (<year>2009</year>) <volume>69</volume>:<fpage>7619</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4199</pub-id><pub-id pub-id-type="pmid">19752089</pub-id></mixed-citation>
</ref>
<ref id="B212">
<label>212.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>F</given-names></name><name><surname>Kondo</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Kusumi</surname><given-names>T</given-names></name><name><surname>Fujimoto</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Period is involved in the proliferation of human pancreatic MIA-PaCa2 cancer cells by TNF-alpha</article-title>. <source/>Biomed Res. (<year>2008</year>) <volume>29</volume>:<fpage>99</fpage>–<lpage>103</lpage>. <pub-id pub-id-type="doi">10.2220/biomedres.29.99</pub-id><pub-id pub-id-type="pmid">18480551</pub-id></mixed-citation>
</ref>
<ref id="B213">
<label>213.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafaie</surname><given-names>N</given-names></name><name><surname>Kallay</surname><given-names>E</given-names></name><name><surname>Sauerzapf</surname><given-names>E</given-names></name><name><surname>Bonner</surname><given-names>E</given-names></name><name><surname>Kriwanek</surname><given-names>S</given-names></name><name><surname>Cross</surname><given-names>HS</given-names></name><etal></etal></person-group>. <article-title>Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer</article-title>. <source/>Mol Carcinogenes. (<year>2009</year>) <volume>48</volume>:<fpage>642</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/mc.20510</pub-id><pub-id pub-id-type="pmid">19148895</pub-id></mixed-citation>
</ref>
<ref id="B214">
<label>214.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>MY</given-names></name><name><surname>Yang</surname><given-names>WC</given-names></name><name><surname>Lin</surname><given-names>PM</given-names></name><name><surname>Hsu</surname><given-names>JF</given-names></name><name><surname>Hsiao</surname><given-names>HH</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name><etal></etal></person-group>. <article-title>Altered expression of circadian clock genes in human chronic myeloid leukemia</article-title>. <source/>J Biol Rhythms. (<year>2011</year>) <volume>26</volume>:<fpage>136</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1177/0748730410395527</pub-id><pub-id pub-id-type="pmid">21454294</pub-id></mixed-citation>
</ref>
<ref id="B215">
<label>215.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujioka</surname><given-names>A</given-names></name><name><surname>Takashima</surname><given-names>N</given-names></name><name><surname>Shigeyoshi</surname><given-names>Y</given-names></name></person-group>. <article-title>Circadian rhythm generation in a glioma cell line</article-title>. <source/>Biochem Biophys Res Commun. (<year>2006</year>) <volume>346</volume>:<fpage>169</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2006.05.094</pub-id><pub-id pub-id-type="pmid">16750513</pub-id></mixed-citation>
</ref>
<ref id="B216">
<label>216.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>HC</given-names></name><name><surname>Niu</surname><given-names>ZF</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>SZ</given-names></name><name><surname>Hao</surname><given-names>SC</given-names></name><name><surname>Liu</surname><given-names>ZT</given-names></name><etal></etal></person-group>. <article-title>Deregulated expression of the Per1 and Per2 in human gliomas</article-title>. <source/>Canadian J Neurol Sci. (<year>2010</year>) <volume>37</volume>:<fpage>365</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1017/S031716710001026X</pub-id><pub-id pub-id-type="pmid">20481271</pub-id></mixed-citation>
</ref>
<ref id="B217">
<label>217.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prigogine</surname><given-names>I</given-names></name></person-group>. <article-title>Life and physics. New perspectives</article-title>. <source/>Cell Biophys. (<year>1986</year>) <volume>9</volume>:<fpage>217</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4612-4834-7_13</pub-id><pub-id pub-id-type="pmid">2436795</pub-id></mixed-citation>
</ref>
<ref id="B218">
<label>218.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Atkins</surname><given-names>PW</given-names></name></person-group>
<source/>Physical Chemistry, 5th Edn. <publisher-loc>Oxford; Melbourne, VIC; Tokio</publisher-loc>: <publisher-name>Oxford University Press</publisher-name> (<year>1990</year>).</mixed-citation>
</ref>
<ref id="B219">
<label>219.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruffell</surname><given-names>B</given-names></name><name><surname>Au</surname><given-names>A</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Esserman</surname><given-names>LJ</given-names></name><name><surname>Hwang</surname><given-names>ES</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name></person-group>. <article-title>Leukocyte composition of human breast cancer</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2012</year>) <volume>109</volume>:<fpage>2796</fpage>–<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1104303108</pub-id><pub-id pub-id-type="pmid">21825174</pub-id></mixed-citation>
</ref>
<ref id="B220">
<label>220.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>TT</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name></person-group>. <article-title>Humoral immunity, inflammation and cancer</article-title>. <source/>Curr Opin Immunol. (<year>2007</year>) <volume>19</volume>:<fpage>209</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2007.01.001</pub-id><pub-id pub-id-type="pmid">17276050</pub-id></mixed-citation>
</ref>
<ref id="B221">
<label>221.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>J</given-names></name><name><surname>Jung</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Sheng</surname><given-names>H</given-names></name></person-group>. <article-title>Prostaglandin E2 stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer</article-title>. <source/>J Biol Chem. (<year>2005</year>) <volume>280</volume>:<fpage>26565</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M413056200</pub-id><pub-id pub-id-type="pmid">15899904</pub-id></mixed-citation>
</ref>
<ref id="B222">
<label>222.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellone</surname><given-names>MD</given-names></name><name><surname>Teramoto</surname><given-names>H</given-names></name><name><surname>Williams</surname><given-names>BO</given-names></name><name><surname>Druey</surname><given-names>KM</given-names></name><name><surname>Gutkind</surname><given-names>JS</given-names></name></person-group>. <article-title>Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis</article-title>. <source/>Science. (<year>2005</year>) <volume>310</volume>:<fpage>1504</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1126/science.1116221</pub-id><pub-id pub-id-type="pmid">16293724</pub-id></mixed-citation>
</ref>
<ref id="B223">
<label>223.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricchi</surname><given-names>P</given-names></name><name><surname>Zarrilli</surname><given-names>R</given-names></name><name><surname>Di Palma</surname><given-names>A</given-names></name><name><surname>Acquaviva</surname><given-names>AM</given-names></name></person-group>. <article-title>Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy</article-title>. <source/>Br J Cancer. (<year>2003</year>) <volume>88</volume>:<fpage>803</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6600829</pub-id><pub-id pub-id-type="pmid">12644813</pub-id></mixed-citation>
</ref>
<ref id="B224">
<label>224.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goessling</surname><given-names>W</given-names></name><name><surname>North</surname><given-names>TE</given-names></name><name><surname>Loewer</surname><given-names>S</given-names></name><name><surname>Lord</surname><given-names>AM</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Stoick-Cooper</surname><given-names>CL</given-names></name><etal></etal></person-group>. <article-title>Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration</article-title>. <source/>Cell. (<year>2009</year>) <volume>136</volume>:<fpage>1136</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2009.01.015</pub-id><pub-id pub-id-type="pmid">19303855</pub-id></mixed-citation>
</ref>
<ref id="B225">
<label>225.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>HT</given-names></name><name><surname>Nellore</surname><given-names>A</given-names></name><name><surname>Patsoukis</surname><given-names>N</given-names></name><name><surname>Petkova</surname><given-names>V</given-names></name><name><surname>McDonough</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT</article-title>. <source/>Blood Cancer J. (<year>2014</year>) <volume>4</volume>:<fpage>e178</fpage>. <pub-id pub-id-type="doi">10.1038/bcj.2013.75</pub-id><pub-id pub-id-type="pmid">24442207</pub-id></mixed-citation>
</ref>
<ref id="B226">
<label>226.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>CT</given-names></name><name><surname>Ahmad</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Crawford</surname><given-names>DA</given-names></name></person-group>. <article-title>Prostaglandin E2 alters Wnt-dependent migration and proliferation in neuroectodermal stem cells: implications for autism spectrum disorders</article-title>. <source/>Cell Commun Signal. (<year>2014</year>) <volume>12</volume>:<fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/1478-811X-12-19</pub-id><pub-id pub-id-type="pmid">24656144</pub-id></mixed-citation>
</ref>
<ref id="B227">
<label>227.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallee</surname><given-names>A</given-names></name><name><surname>Lecarpentier</surname><given-names>Y</given-names></name><name><surname>Vallee</surname><given-names>JN</given-names></name></person-group>. <article-title>Thermodynamic aspects and reprogramming cellular energy metabolism during the fibrosis process</article-title>. <source/>Int J Mol Sci. (<year>2017</year>) <volume>18</volume>:<fpage>E2537</fpage>. <pub-id pub-id-type="doi">10.3390/ijms18122537</pub-id><pub-id pub-id-type="pmid">29186898</pub-id></mixed-citation>
</ref>
<ref id="B228">
<label>228.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiavegato</surname><given-names>A</given-names></name><name><surname>Bochaton-Piallat</surname><given-names>ML</given-names></name><name><surname>D'Amore</surname><given-names>E</given-names></name><name><surname>Sartore</surname><given-names>S</given-names></name><name><surname>Gabbiani</surname><given-names>G</given-names></name></person-group>. <article-title>Expression of myosin heavy chain isoforms in mammary epithelial cells and in myofibroblasts from different fibrotic settings during neoplasia</article-title>. <source/>Virchows Archiv. (<year>1995</year>) <volume>426</volume>:<fpage>77</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1007/BF00194701</pub-id><pub-id pub-id-type="pmid">7535633</pub-id></mixed-citation>
</ref>
<ref id="B229">
<label>229.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>S</given-names></name><name><surname>Sakurai</surname><given-names>K</given-names></name><name><surname>Shinomiya</surname><given-names>T</given-names></name><name><surname>Fujitani</surname><given-names>N</given-names></name><name><surname>Key</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>M</given-names></name></person-group>. <article-title>Biochemical and immunohistochemical characterization of the isoforms of myosin and actin in human placenta</article-title>. <source/>Placenta. (<year>2011</year>) <volume>32</volume>:<fpage>347</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2011.02.008</pub-id><pub-id pub-id-type="pmid">21420731</pub-id></mixed-citation>
</ref>
<ref id="B230">
<label>230.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y</given-names></name><name><surname>Claes</surname><given-names>V</given-names></name><name><surname>Lecarpentier</surname><given-names>E</given-names></name><name><surname>Guerin</surname><given-names>C</given-names></name><name><surname>Hebert</surname><given-names>JL</given-names></name><name><surname>Arsalane</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Ultraslow myosin molecular motors of placental contractile stem villi in humans</article-title>. <source/>PLoS ONE. (<year>2014</year>) <volume>9</volume>:<fpage>e108814</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0108814</pub-id><pub-id pub-id-type="pmid">25268142</pub-id></mixed-citation>
</ref>
<ref id="B231">
<label>231.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecarpentier</surname><given-names>Y</given-names></name><name><surname>Claes</surname><given-names>V</given-names></name><name><surname>Hebert</surname><given-names>JL</given-names></name><name><surname>Krokidis</surname><given-names>X</given-names></name><name><surname>Blanc</surname><given-names>FX</given-names></name><name><surname>Michel</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Statistical mechanics of the human placenta: a stationary state of a near-equilibrium system in a linear regime</article-title>. <source/>PLoS ONE. (<year>2015</year>) <volume>10</volume>:<fpage>e0142471</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0142471</pub-id><pub-id pub-id-type="pmid">26569482</pub-id></mixed-citation>
</ref>
<ref id="B232">
<label>232.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabbiani</surname><given-names>G</given-names></name><name><surname>Hirschel</surname><given-names>BJ</given-names></name><name><surname>Ryan</surname><given-names>GB</given-names></name><name><surname>Statkov</surname><given-names>PR</given-names></name><name><surname>Majno</surname><given-names>G</given-names></name></person-group>. <article-title>Granulation tissue as a contractile organ. A study of structure and function</article-title>. <source/>J Exp Med. (<year>1972</year>) <volume>135</volume>:<fpage>719</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1084/jem.135.4.719</pub-id><pub-id pub-id-type="pmid">4336123</pub-id></mixed-citation>
</ref>
<ref id="B233">
<label>233.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabbiani</surname><given-names>G</given-names></name></person-group>. <article-title>The myofibroblast: a key cell for wound healing and fibrocontractive diseases</article-title>. <source/>Prog Clin Biol Res. (<year>1981</year>) <volume>54</volume>:<fpage>183</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="pmid">7015359</pub-id></mixed-citation>
</ref>
<ref id="B234">
<label>234.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinz</surname><given-names>B</given-names></name><name><surname>Phan</surname><given-names>SH</given-names></name><name><surname>Thannickal</surname><given-names>VJ</given-names></name><name><surname>Galli</surname><given-names>A</given-names></name><name><surname>Bochaton-Piallat</surname><given-names>ML</given-names></name><name><surname>Gabbiani</surname><given-names>G</given-names></name></person-group>. <article-title>The myofibroblast: one function, multiple origins</article-title>. <source/>Am J Pathol. (<year>2007</year>) <volume>170</volume>:<fpage>1807</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2007.070112</pub-id><pub-id pub-id-type="pmid">17525249</pub-id></mixed-citation>
</ref>
</ref-list>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item>
<term>APC</term>
<def>
<p>adenomatous polyposis coli</p>
</def>
</def-item>
<def-item>
<term>AEC</term>
<def>
<p>alveolar epithelial cells</p>
</def>
</def-item>
<def-item>
<term>BMAL1</term>
<def>
<p>circadian brain and muscle aryl-hydrocarbon receptor nuclear translocator-like1</p>
</def>
</def-item>
<def-item>
<term>CR</term>
<def>
<p>circadian rhythm</p>
</def>
</def-item>
<def-item>
<term>CTGF</term>
<def>
<p>connective tissue growth factor</p>
</def>
</def-item>
<def-item>
<term>CTLA-4</term>
<def>
<p>cytotoxic T lymphocyte-associated antigen-4</p>
</def>
</def-item>
<def-item>
<term>DCs</term>
<def>
<p>Dendritic Cells</p>
</def>
</def-item>
<def-item>
<term>DKK1</term>
<def>
<p>dickkopf-1</p>
</def>
</def-item>
<def-item>
<term>DSH</term>
<def>
<p>disheveled</p>
</def>
</def-item>
<def-item>
<term>EGF</term>
<def>
<p>epidermal growth factor</p>
</def>
</def-item>
<def-item>
<term>EMT</term>
<def>
<p>epithelial-mesenchymal transition</p>
</def>
</def-item>
<def-item>
<term>FGF</term>
<def>
<p>fibroblast growth factor</p>
</def>
</def-item>
<def-item>
<term>FZD</term>
<def>
<p>Frizzled</p>
</def>
</def-item>
<def-item>
<term>Glu</term>
<def>
<p>glucose transporter</p>
</def>
</def-item>
<def-item>
<term>GSK-3β</term>
<def>
<p>glycogen synthase kinase-3β</p>
</def>
</def-item>
<def-item>
<term>HGF</term>
<def>
<p>hepatocyte growth factor</p>
</def>
</def-item>
<def-item>
<term>HIF</term>
<def>
<p>hypoxia-inducible transcription factor</p>
</def>
</def-item>
<def-item>
<term>IRF8</term>
<def>
<p>interferon regulatory factor 8</p>
</def>
</def-item>
<def-item>
<term>LDH</term>
<def>
<p>lactate dehydrogenase</p>
</def>
</def-item>
<def-item>
<term>LAP</term>
<def>
<p>latency-associated peptide</p>
</def>
</def-item>
<def-item>
<term>LTBP-1</term>
<def>
<p>latent TGF-β1 binding protein-1</p>
</def>
</def-item>
<def-item>
<term>CLOCK</term>
<def>
<p>locomotor output cycles kaput</p>
</def>
</def-item>
<def-item>
<term>LRP5/6</term>
<def>
<p>low-density lipoprotein receptor-related protein 5/6</p>
</def>
</def-item>
<def-item>
<term>MCT-1</term>
<def>
<p>monocarboxylate lactate transporter-1</p>
</def>
</def-item>
<def-item>
<term>NMMIIA</term>
<def>
<p>non-muscle myosin IIA</p>
</def>
</def-item>
<def-item>
<term>PER</term>
<def>
<p>period</p>
</def>
</def-item>
<def-item>
<term>PPARγ</term>
<def>
<p>peroxisome proliferator-activated receptor gamma</p>
</def>
</def-item>
<def-item>
<term>PI3K</term>
<def>
<p>phosphatidyl-inositol 3-kinase</p>
</def>
</def-item>
<def-item>
<term>PDGF</term>
<def>
<p>platelet-derived growth factor</p>
</def>
</def-item>
<def-item>
<term>PTEN</term>
<def>
<p>phosphatase and tensin homolog</p>
</def>
</def-item>
<def-item>
<term>PFK</term>
<def>
<p>phosphofructokinase</p>
</def>
</def-item>
<def-item>
<term>AKT</term>
<def>
<p>protein kinase B</p>
</def>
</def-item>
<def-item>
<term>PD-1</term>
<def>
<p>programmed cell death protein1</p>
</def>
</def-item>
<def-item>
<term>PDH</term>
<def>
<p>pyruvate dehydrogenase complex</p>
</def>
</def-item>
<def-item>
<term>PDK</term>
<def>
<p>pyruvate dehydrogenase kinase</p>
</def>
</def-item>
<def-item>
<term>PKM2</term>
<def>
<p>pyruvate kinase M2</p>
</def>
</def-item>
<def-item>
<term>RTK</term>
<def>
<p>receptor tyrosine kinase</p>
</def>
</def-item>
<def-item>
<term>Treg cell</term>
<def>
<p>Regulatory T cell</p>
</def>
</def-item>
<def-item>
<term>SLC</term>
<def>
<p>small latent complex</p>
</def>
</def-item>
<def-item>
<term>SMA</term>
<def>
<p>smooth muscle actin</p>
</def>
</def-item>
<def-item>
<term>ECM</term>
<def>
<p>extracellular matrix</p>
</def>
</def-item>
<def-item>
<term>TCF/LEF</term>
<def>
<p>T-cell factor/lymphoid enhancer factor</p>
</def>
</def-item>
<def-item>
<term>TGF</term>
<def>
<p>Transforming Growth Factor</p>
</def>
</def-item>
<def-item>
<term>Th</term>
<def>
<p>T helper</p>
</def>
</def-item>
<def-item>
<term>TCA</term>
<def>
<p>tricarboxylic acid</p>
</def>
</def-item>
<def-item>
<term>TNF-β</term>
<def>
<p>tumor necrosis factor beta</p>
</def>
</def-item>
<def-item>
<term>VEGF</term>
<def>
<p>vascular endothelial growth factor.</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>
</pmc-articleset>